<SEC-DOCUMENT>0001178913-20-002260.txt : 20200805
<SEC-HEADER>0001178913-20-002260.hdr.sgml : 20200805
<ACCEPTANCE-DATETIME>20200805085529
ACCESSION NUMBER:		0001178913-20-002260
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20200805
FILED AS OF DATE:		20200805
DATE AS OF CHANGE:		20200805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		201075863

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zkzk2024746.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 7.0.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><br>
    <div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">Form 6-K</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">For the month of August 2020</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Commission File Number 000-30902</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">COMPUGEN LTD.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
      <table cellspacing="0" cellpadding="0" id="z03cfb97595724edab11d281d14c1c822" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">26&#160;Harokmim Street</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Holon 5885849, Israel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
      <div style="line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Form 20-F&#160; &#9746; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F&#160; &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compugen Ltd.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">On or about August 5, 2020, the Company first distributed copies of its proxy statement to its shareholders and will mail to its shareholders of record a proxy statement for an Annual General
          Meeting of Shareholders to be held on September 16, 2020 in Israel.</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">
          <div style="background-color: #FFFFFF; line-height: 1.25;">
            <div style="line-height: 1.25;">A copy of the notice of 2020 Annual General Meeting of Shareholders, proxy statement and proxy card are attached to this Form
              6-K as Exhibit 99.1.</div>
          </div>
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
        <div style="line-height: 1.25;">The information contained in this Form 6-K is hereby incorporated by reference into the Company&#8217;s Registration Statements on Form F-3, File No.&#160;<font style="background-color: #FFFFFF;">333-233001 and File No.
            333-240183</font>.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Exhibits</div>
      <div style="line-height: 1.25; font-weight: bold;">Exhibit</div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z1ef74a9b0df14defafa8dd0cf13cd607">

            <tr>
              <td style="width: 6%;">
                <div><font style="font-weight: bold;"><u>Number</u></font></div>
              </td>
              <td style="width: 94%;">
                <div><font style="font-weight: bold;"><u>Description of Exhibit</u></font></div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 6%;">&#160;</td>
              <td rowspan="1" style="width: 94%;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 6%;" rowspan="1"><a href="exhibit_99-1.htm">99.1</a></td>
              <td style="width: 94%;" rowspan="1"><a href="exhibit_99-1.htm">Notice of 2020 Annual General Meeting of Shareholders, Proxy Statement and Proxy Card.</a></td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Signatures</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zb335e077d5cf48a1bc9db1faefe6e106" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="vertical-align: bottom;" colspan="3">
              <div style="line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: middle;" colspan="4">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Date: August 5, 2020</div>
            </td>
            <td style="width: 4%; vertical-align: bottom;">
              <div style="line-height: 1.25;">By:&#160;</div>
            </td>
            <td style="width: 25%; vertical-align: bottom; border-bottom: 2px solid black;">
              <div style="line-height: 1.25;">/s/ Eran Ben Dor&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td style="width: 21%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 25%; vertical-align: middle;">&#160;</td>
            <td style="width: 21%; vertical-align: middle;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: bottom;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 25%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Eran Ben Dor</div>
              <div style="line-height: 1.25;">General Counsel</div>
            </td>
            <td style="width: 21%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 7.0.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="line-height: 1.25; text-align: center;">
        <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
        </div>
        <div><br>
        </div>
        <img src="image00002.jpg"></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: right; line-height: 1.25;">August 5, 2020</div>
      <div style="line-height: 1.25">&#160; <br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Dear Shareholder,</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">You are cordially invited to attend, and notice is hereby given of, the 2020 Annual General Meeting of Shareholders of Compugen Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) to be
        held at the Company&#8217;s offices at 26 Harokmim Street, Bldg. D, Holon, Israel, on September 16, 2020 at 5:00 PM (Israel time) (the &#8220;<font style="font-weight: bold;">Meeting</font>&#8221;) for the following purposes:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za790fe96ab0c4c31a1f0881ac4b96772">

          <tr>
            <td style="width: 21.3pt;"><br>
            </td>
            <td style="width: 14.15pt; vertical-align: top; align: right;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To re-elect seven (7) directors to serve as members of the Board of Directors of the Company (the &#8220;<font style="font-weight: bold;">Board of Directors</font>&#8221;);</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze1cd043bb76848c1b2faade99b95e580">

          <tr>
            <td style="width: 21.3pt;"><br>
            </td>
            <td style="width: 14.15pt; vertical-align: top; align: right;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To approve the Amended and Restated Compensation Policy of the Company;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfe83ac421c8c4fd7a5474829c79c5c25">

          <tr>
            <td style="width: 21.3pt;"><br>
            </td>
            <td style="width: 14.15pt; vertical-align: top; align: right;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To approve compensation to the Company&#8217;s Chief Executive Officer;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfa20eabbd57948f59d038c441df38cdd">

          <tr>
            <td style="width: 21.3pt;"><br>
            </td>
            <td style="width: 14.15pt; vertical-align: top; align: right;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To approve an annual equity award plan to the non-executive members of the Board of Directors; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3d5f4b66798649a1988eabfa1824783f">

          <tr>
            <td style="width: 21.3pt;"><br>
            </td>
            <td style="width: 14.15pt; vertical-align: top; align: right;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To re-appoint Kost Forer Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global), as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2020, and until the next annual general
                meeting and to authorize the Board, upon recommendation of the Audit Committee, to determine the remuneration of Kost Forer Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global), in accordance with the volume and nature of its
                services.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">In addition, at the Meeting, shareholders will also have an opportunity to discuss the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2019; this
        item will not involve a vote of the shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Should changes be made to any item on the agenda for the Meeting after the publication of this proxy statement, the Company will communicate the changes to its shareholders through the publication
        of a press release, a copy of which will be filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;) on a Report <font style="background-color: #FFFFFF;">on Form 6-K and with the Israeli Securities
          Authority (the &#8220;</font><font style="background-color: #FFFFFF; font-weight: bold;">ISA</font><font style="background-color: #FFFFFF;">&#8221;).</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">Only shareholders of record at the close of business day on Monday, August 10, 2020, the record date for determining those shareholders eligible to vote at
          the Meeting, are entitled to vote at the Meeting and at any postponements or adjournments thereof. All such shareholders are cordially invited to attend the Meeting in person.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">We currently intend to hold the Meeting in person, subject to the Israeli Ministry of Health&#8217;s COVID-19 restrictions. However, depending on developments
          with respect to the COVID-19 pandemic, we might hold the Meeting virtually on the above date and time instead of in person. If we determine that a change to a virtual meeting format is advisable or required, an announcement of such change </font>will






        be filed with the SEC on a Report on Form 6-K and with the ISA as<font style="background-color: #FFFFFF;"> promptly as practicable.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Whether or not you plan to attend the Meeting, you are urged to promptly complete, date and sign the enclosed proxy and to mail it in the enclosed envelope, which requires no postage if mailed in
        the United States. A shareholder, whose shares are registered with a member of the Tel-Aviv Stock Exchange Ltd. (the &#8220;<font style="font-weight: bold;">TASE</font>&#8221;), and intends to vote his or her shares by proxy, should deliver or mail (via
        registered mail) his or her completed proxy to the Company&#8217;s offices, attention: General Counsel, together with an ownership certificate confirming his or her ownership of the Company&#8217;s shares as of the record date, which certificate must be
        approved by a recognized financial institution, i.e. that TASE member through which he or she holds Company&#8217;s shares, as required by the Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting), 2000, as amended.
        Such shareholder is entitled to receive the ownership certificate in a branch of the relevant TASE member or by mail to his or her address, if the shareholder so requests. Such a request must be made in advance for a particular securities account.
        Alternatively, a shareholder who holds shares through members of TASE may vote electronically via the electronic voting system of the ISA (the &#8220;<font style="font-weight: bold;">Electronic Voting System</font>&#8221;), after receiving a personal
        identifying number, an access code and additional information regarding this Meeting from the member of the TASE and after carrying out a secured identification process,&#160;up to six (6) hours before the time set for the Meeting. If applicable, a
        shareholder may request instructions about such electronic voting from the TASE member through which he or she holds Company&#8217;s shares.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; line-height: 1.25;">Execution and return of a shareholder&#8217;s proxy will not deprive such shareholder of his or her right to attend the Meeting and vote in person, and any person giving a proxy has the right to revoke
        it any time before it is exercised.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Joint holders of shares should take note that, pursuant to Article 37(d) of the Articles of Association of the Company, the vote of the senior holder who tenders a vote, in person, by proxy, by
        proxy card or by electronic voting, will be accepted to the exclusion of any vote(s) of the other joint holder(s), and for this purpose seniority will be determined by the order in which the names appear in the Company&#8217;s register of shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A proxy will be effective only if it is received at the Company&#8217;s office no later than twenty four (24) hours prior to the time of the Meeting (i.e., 5:00 PM Israel time on
        September 15, 2020), or, in case of a shareholder voting electronically through the Electronic Voting System, no later than six (6) hours prior to the time of the Meeting (i.e., 11:00 AM Israel time on September 16, 2020).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" id="ze097996c1a7c463a83f78ffc2aa3a44e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50%;">
                <div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By Order of the Board of Directors,</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>/s/ Mr. Paul Sekhri</u></div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Paul Sekhri</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Chairman of the Board</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Holon, Israel</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">August 5, 2020</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROXY STATEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">26 Harokmim Street, Bldg. D</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Holon, Israel</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">2020 Annual General Meeting of Shareholders</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps;">To be Held on September 16, 2020</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">This proxy statement is being furnished to the holders of ordinary shares, New Israeli Shekels (&#8220;<font style="font-weight: bold;">NIS</font>&#8221;) 0.01 nominal (par) value per share (&#8220;<font style="font-weight: bold;">Ordinary Shares</font>&#8221; or &#8220;<font style="font-weight: bold;">Shares</font>&#8221;) of Compugen Ltd. (&#8220;<font style="font-weight: bold;">Compugen</font>&#8221; or the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) in connection
        with the solicitation by the Board of Directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221; or &#8220;<font style="font-weight: bold;">Board of Directors</font>&#8221;) of proxies for use at the Company&#8217;s 2020 Annual General Meeting of
        Shareholders, or at any adjournment or postponement thereof (the &#8220;<font style="font-weight: bold;">Meeting</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Meeting will be held on September 16, 2020, at 5:00 PM (Israel time), at the Company&#8217;s offices at 26 Harokmim Street, Bldg. D, Holon, Israel, for the following purposes:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z032784ac825f46a595086c6a039ff83a">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To re-elect seven (7) directors to serve as members of the Board of Directors;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0a3a0cf7547f410599d31bfd39c347ec">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To approve the Amended and Restated Compensation Policy of the Company;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6158dd05a0574adb82d2844c3e1cb351">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To approve compensation to the Company&#8217;s Chief Executive Officer;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z27e969ba3278440791861d506ca657aa">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To approve an annual equity award plan to the non-executive members of the Board of Directors; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8f21c5d1379a45bfbf0f247782b9cf2a">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To re-appoint Kost Forer Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global), as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2020, and until the next annual general
                and to authorize the Board, upon recommendation of the Audit Committee, to determine the remuneration of Kost Forer Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global), in accordance with the volume and nature of its services.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">In addition, at the Meeting, shareholders will also have an opportunity to discuss the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2019. This
        item will not involve a vote of the shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Should changes be made to any item on the agenda for the Meeting after the publication of this proxy statement, the Company will communicate the changes to its shareholders through the publication
        of a press release, a copy of which will be filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;) on a Report on Form 6-K and with the Israeli Securities Authority (the &#8220;<font style="font-weight: bold;">ISA</font>&#8221;).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">We currently intend to hold the Meeting in person, subject to the Israeli Ministry of Health&#8217;s COVID-19 restrictions. However, depending on developments
          with respect to the COVID-19 pandemic, we might hold the Meeting virtually on the above date and time instead of in person. If we determine that a change to a virtual meeting format is advisable or required, an announcement of such change </font>will






        be filed with the SEC on a Report on Form 6-K and with the ISA as<font style="background-color: #FFFFFF;"> promptly as practicable.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">RECORD DATE AND VOTING RIGHTS</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Only holders of record of Ordinary Shares at the close of business on Monday, August 10, 2020, the record date for determining those shareholders eligible to vote at the Meeting, will be entitled
        to notice of and to vote at the Meeting and any postponements or adjournments thereof. At such time, each issued and outstanding Ordinary Share will be entitled to one vote upon each of the matters to be presented at the Meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROXY PROCEDURE</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">A form of proxy for use at the Meeting and a return envelope for the proxy are also enclosed.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">If specified by a shareholder on the form of proxy, the Shares represented thereby will be voted in accordance with such specification. If a choice is not specified by a shareholder with respect to
        any proposal, the form of proxy will be voted &#8220;FOR&#8221; any such proposal and in the discretion of the proxies with respect to all other matters which may properly come before the meeting and any and all adjournments thereof. On all matters considered
        at the Meeting, abstentions and broker non-votes will be treated as neither a vote &#8220;FOR&#8221; nor &#8220;AGAINST&#8221; the matter, although they will be counted in determining if a quorum is present. Broker non-votes are votes that brokers holding shares of record
        for their clients are, pursuant to applicable stock exchange or other rules, precluded from casting in respect of certain non-routine proposals because such brokers have not received specific instructions from their clients as to the manner in
        which such shares should be voted on those proposals and as to which the brokers have advised the Company that, accordingly, they lack voting authority.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">3</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">A shareholder, whose Shares are registered with a member of the TASE, and intends to vote his or her shares by proxy, should deliver or mail (via registered mail) his or her completed proxy to the
        Company&#8217;s offices, attention: General Counsel, together with an ownership certificate confirming his or her ownership of the Company&#8217;s shares as of the record date, which certificate must be approved by a recognized financial institution, i.e. that
        TASE member through which he or she hold their shares, as required by the Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting), 2000, as amended. Such shareholder is entitled to receive the ownership
        certificate in a branch of the relevant TASE member or by mail to his or her address, if the shareholder so requests. Such a request must be made in advance for a particular securities account. Alternatively, a shareholder who holds shares through
        members of TASE may vote electronically via the electronic voting system of the ISA (the &#8220;<font style="font-weight: bold;">Electronic Voting System</font>&#8221;), after receiving a personal identifying number, an access code and additional information
        regarding this Meeting from the member of the TASE and after carrying out a secured identification process, up to six (6) hours before the time set for the Meeting. If applicable, a shareholder may request instructions about such electronic voting
        from the TASE member through which he or she holds Company&#8217;s shares.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Joint holders of shares should take note that, pursuant to Article 37(d) of the Articles of Association of the Company, the vote of the senior holder who tenders a vote, in person, by proxy, by
        proxy card or by electronic voting, will be accepted to the exclusion of any vote(s) of the other joint holder(s), and for this purpose seniority will be determined by the order in which the names appear in the Company&#8217;s register of shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A proxy will be effective only if it is received at the Company&#8217;s office no later than twenty four (24) hours prior to the time of the Meeting (i.e., 5:00 PM Israel time on
        September 15, 2020), or, in case of a shareholder voting electronically through the Electronic Voting System, no later than six (6) hours prior to the time of the Meeting (i.e., 11:00 AM Israel time on September 16, 2020).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">A shareholder may revoke the authority granted by execution of his or her proxy at any time before the effective exercise thereof by: (i) filing with the Company a written notice of revocation or
        duly executed proxy bearing a later date; (ii) electronically voting through the Electronic Voting System at a later date (but no later than six (6) hours prior to the time of the Meeting); or (iii) voting in person at the Meeting. However,
        attendance at the Meeting will not in and of itself constitute revocation of proxy, and if a shareholder attends the Meeting and does not elect to vote in person, his or her proxy or electronic voting through the Electronic Voting System will not
        be revoked.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Proxies for use at the Meeting are being solicited by the Board of Directors of the Company mainly by mail. The Company will bear the cost for the solicitation of the proxies, including postage,
        printing and handling, and will reimburse the reasonable expenses of brokerage firms and others for forwarding material to beneficial owners of Ordinary Shares. The Company has retained MacKenzie Partners, Inc. to act as the Company&#8217;s solicitation
        agent and to assist with the solicitation of proxies for a fee of $15,000 plus reimbursable expenses. In addition to solicitation by mail, certain of the Company&#8217;s officers, directors, employees, consultants and agents may solicit proxies by
        telephone, electronic mail or other personal contact. Other than as set forth above with respect to the solicitation agent, none of the aforementioned officers, directors, employees, consultants or agents of the Company will receive additional
        compensation for such solicitation.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">QUORUM</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Two or more shareholders present in person, by proxy or by voting through the Electronic Voting System and holding together Ordinary Shares conferring in the aggregate twenty five percent or more
        of the voting power of the Company, shall constitute a quorum at the Meeting. If within half an hour from the time set for the meeting a quorum is not present, the Meeting shall stand adjourned to September 23, 2020, at the same time and place. At
        such adjourned meeting, any two shareholders present in person, by proxy or by voting through the Electronic Voting System, shall constitute a quorum.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">4</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-weight: bold;">BENEFICIAL OWNERSHIP OF SECURITIES BY PRINCIPAL</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SHAREHOLDERS AND MANAGEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The following table sets forth certain information as of July 30, 2020 regarding (i) persons or entities known to the Company to beneficially own more than 5% of the Company&#8217;s outstanding Ordinary
        Shares, (ii) each &#8220;office holder&#8221;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>, as such term is defined in the Israeli Companies Law, 5759-1999 (the &#8220;<font style="font-weight: bold;">Companies Law</font>&#8221;) of the Company (the &#8220;<font style="font-weight: bold;">Office Holders</font>&#8221;)






        known to the Company to beneficially own more than 1% of the Company&#8217;s issued and outstanding Ordinary Shares (to the extent applicable); and (iii) all Office Holders as a group.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The information contained in the table below has been obtained from the Company&#8217;s records or disclosed in public filings with the SEC.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Except where otherwise indicated, and except pursuant to community property laws, we believe, based on information furnished by such owners, that the beneficial owners of the Ordinary Shares listed
        below have sole investment and voting power with respect to such Shares.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Total &#8220;Number of Ordinary Shares Beneficially Owned&#8221; in the table below include Shares that may be acquired by an individual or group upon the exercise of options that are either currently
        exercisable or will become exercisable within 60&#160;days of July 30, 2020.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The shareholders listed below do not have any different voting rights from any of our other shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z8677887c4b2348c2ab8cfc9b7db5983c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-weight: bold;">Beneficial Owner</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: &#38;quot; font-weight: bold;">Number of Ordinary Shares Beneficially Owned</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: &#38;quot; font-weight: bold;">Percent of Ordinary Shares Beneficially Owned<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;">
              <div style="text-align: justify; line-height: 1.25;">ARK Investment Management LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">8,975,310</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">10.83</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(255, 255, 255); width: 76%;">
              <div style="text-align: justify; line-height: 1.25;"><font style="font-family: &#38;quot;">Nikko Asset Management Co., Ltd.</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">8,149,982</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">9.84</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 76%;">
              <div style="text-align: justify; line-height: 1.25;"><font style="font-family: &#38;quot;">Sumitomo Mitsui Trust Holdings, Inc.</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">8,149,982</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">9.84</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(255, 255, 255); width: 76%;">
              <div style="text-align: justify; line-height: 1.25;">All Office Holders, including directors, as a group (consists of 14 persons)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">2,071,695</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">2.44</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25; font-family: &#38;quot;">%</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze35708ff0ad64041834e6dc5574e53d7">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based upon 82,856,804 Ordinary Shares issued and outstanding as of July 30, 2020.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3f8d5764ce584a81b1b09e9cbee2a12c">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based upon information provided by the shareholder in its Form 13G/A filed with the SEC on February 14, 2020. With respect to the ordinary shares reported in its Schedule 13G/A, ARK Investment Management LLC, or ARK, indicated as having
                (i) sole voting power with respect to 8,740,866 ordinary shares, (ii) shared voting power with respect to 91,315 ordinary shares, (iii) sole dispositive power with respect to 8,975,310 ordinary shares, and (iv) no shared dispositive power
                with respect to ordinary shares. Furthermore, in such filing ARK indicated aggregate beneficial ownership of 8,975,310 ordinary shares. The address of the principal business office of ARK is 3 East 28th Street, 7th Floor, New York, NY
                10016.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;<br>
      </div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="59d2d6e9d6e245ca8cba792e446bc1c2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Based upon information provided by the shareholder in its Schedule 13G/A filed with the SEC on February 12, 2020. With respect to the ordinary shares reported in the
                Schedule 13G/A, Nikko Asset Management Co., Ltd., or Nikko, indicated as having (i) no sole voting or dispositive power with respect to ordinary shares, (ii) shared voting power with respect to 6,168,753 ordinary shares, and (iii) shared
                dispositive power with respect to 8,149,982 ordinary shares. Furthermore, in such filing Nikko indicated aggregate beneficial ownership of 8,149,982 ordinary shares. The address of the principal business office of Nikko is 605 Third Avenue,
                38th&#160;Floor, New York, NY 10158.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3f71a907965841cca2f37d8980e8d3ef">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based upon information provided by the shareholder in its Schedule 13G/A filed with the SEC on February 12, 2020. With respect to the ordinary shares reported in the Schedule 13G/A, Sumitomo Mitsui Trust Holdings, Inc., or Sumitomo,
                indicated as having (i) no sole voting or dispositive power with respect to ordinary shares and (ii) shared voting power and dispositive power with respect to 8,149,982 ordinary shares. Furthermore, in such filing Sumitomo indicated
                aggregate beneficial ownership of 8,149,982 ordinary shares. The address of the principal business office of Sumitomo is 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">For information relating to the remuneration of our five most highly compensated Office Holders with respect to the year ended December 31, 2019, please see &#8220;Item 6. Directors, Senior Management and Employees - B.
        Compensation - Individual Compensation of Covered Office Holders&#8221; in our Annual Report on Form 20-F for the year ended December 31, 2019, which was filed with the SEC on February 24, 2020 (File No. 000-30902) (the &#8220;<font style="font-weight: bold;">2019






          Form 20-F</font>&#8221;).<br>
        <br>
        <hr noshade="noshade" align="left" style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> The term &#8220;Office Holder&#8221; as defined in the Companies Law includes a director, the chief executive officer, the chief business
          officer, the vice chief executive officer, the deputy chief executive officer, any other person fulfilling or assuming any of the foregoing positions without regard to such person&#8217;s title and any manager who is directly subordinated to the chief
          executive officer. In addition to the current seven members of our Board, the Company defines an additional seven individuals to be Office Holders.</div>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">5</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">ITEM NO. 1</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">RE-ELECTION OF SEVEN (7) DIRECTORS</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-right: 0.3pt; line-height: 1.25; font-weight: bold;">Background</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The articles of association of the Company (the &#8220;<font style="font-weight: bold;">Articles</font>&#8221;) provide that the number of directors to serve on our Board shall be no less than five (5) and no
        more than fourteen (14).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Board is currently comprised of seven (7) members, all of whom have a serving term that expires at the end of the Meeting, and all of whom stand for re-election for a further term of service.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Directors are generally elected at each annual general meeting for a term starting at such meeting and ending at the conclusion of the next annual general meeting of shareholders <font style="background-color: #FFFFFF;">and until his or her respective successor has been elected, or until his or her office </font>is vacated earlier in accordance with the provisions of the Companies Law and the Articles. In accordance with our
        Articles, directors may also be appointed by our Board in between annual general meetings.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-right: 0.3pt; line-height: 1.25; font-weight: bold;">General</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Election</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">At the Meeting, all of the Company&#8217;s current seven (7) directors are candidates for re-election. Following the recommendation of our Nomination and Corporate Governance Committee to the Board in
        accordance with Rule 5605(e) of the Nasdaq Marketplace Rules (&#8220;<font style="font-weight: bold;">Nasdaq Rules</font>&#8221;), it is proposed that Mr. Paul Sekhri, Dr. Anat Cohen-Dayag, Mr. Eran Perry, Mr. Gilead Halevy, Dr. Jean-Pierre Bizzari, Dr.
        Kinneret Livnat Savitzky and Mr. Sandy Zweifach be re-elected as directors. If re-elected, each director nominee will serve for a term ending on the date of the 2021 annual general meeting <font style="background-color: #FFFFFF;">and until his or
          her respective successor has been elected, or until his or her office </font>is vacated earlier in accordance with the provisions of the Companies Law and the Articles.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">In accordance with Israeli law, a nominee for service as a director must submit a declaration to the Company, prior to his or her election, specifying that he or she has the requisite
        qualifications to serve as a director, and the ability to devote the appropriate time to performing his or her duties as such. All candidates for re-election as directors at the Meeting have declared in writing that they possess the requisite
        skills and expertise, as well as sufficient time, to perform their duties as directors of the Company. Other than Dr. Cohen-Dayag, our President and Chief Executive Officer, none of the director nominees has any relationship with the Company.
        Accordingly, our Board determined that all of the director nominees, except for Dr. Cohen-Dayag, qualify as &#8220;independent directors,&#8221; as defined by the Nasdaq Rules. In addition, in accordance with our Board&#8217;s decision in 2018 to adopt certain
        reliefs for companies whose shares are traded in certain foreign stock exchanges, including the Nasdaq Stock Exchange, pursuant to which, if a candidate for service as a director qualifies as independent in accordance with the law of the relevant
        foreign jurisdiction and does not have any affiliation with a controlling shareholder (which is not relevant in our case), the Audit Committee may classify him or her as independent in accordance with the Companies Law, our Audit Committee
        classified each of these candidates, except for Dr. Cohen-Dayag, as independent in accordance with the Companies Law.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">The Company is not aware of any reason why any of the nominees, if elected, would be unable to serve as a director.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">6</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">The names of each director nominee, the year in which such director was first elected to the Board, the age of such director as of July 31, 2020 and his or her service as a member of a committee of
        the Board are as follows<font style="background-color: #FFFFFF;">:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc0af4206e5ea428e9e6751702eac00c2">

          <tr>
            <td style="width: 34%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">Name</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td style="width: 7.06%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Age</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 14.06%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">
                <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Year of First Election</div>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td style="width: 42.19%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25; font-weight: bold;">Positions</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 34%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Paul Sekhri<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 7.06%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">62</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 14.06%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2017</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 42.19%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Chairman of the Board of Directors (Chairman of the Nomination and Corporate Governance Committee)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 34%; vertical-align: middle; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; line-height: 1.25;">Anat Cohen-Dayag, Ph.D.</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 7.06%; vertical-align: bottom; text-align: center; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">53</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 14.06%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; line-height: 1.25;">2014</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 42.19%; vertical-align: middle; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; margin-right: 2.55pt; line-height: 1.25;">President and Chief Executive Officer, Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 34%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Eran Perry<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(2)</sup></div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 7.06%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">49</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 14.06%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">2019</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 42.19%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 2.55pt; line-height: 1.25;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 34%; vertical-align: middle; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; line-height: 1.25;">Gilead Halevy<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 7.06%; vertical-align: bottom; text-align: center; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">53</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 14.06%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; line-height: 1.25;">2018</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 42.19%; vertical-align: middle; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; margin-right: 2.55pt; line-height: 1.25;">Director (Chairman of the Audit Committee)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 34%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Jean-Pierre Bizzari, M.D.</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 7.06%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">65</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 14.06%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 2.55pt; line-height: 1.25;">2018</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 42.19%; vertical-align: middle; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 2.55pt; line-height: 1.25;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 34%; vertical-align: middle; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; line-height: 1.25;">Kinneret Livnat Savitzky, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(3)</sup></div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 7.06%; vertical-align: bottom; text-align: center; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">53</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 14.06%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; line-height: 1.25;">2018</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 42.19%; vertical-align: middle; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; line-height: 1.25;">Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 34%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Sanford (Sandy) Zweifach<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(2)(3)</sup></div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 7.06%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">64</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 14.06%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">2018</div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td style="width: 42.19%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Director (Chairman of the Compensation Committee)</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 18pt; line-height: 1.25;">____________________</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 18pt; line-height: 1.25;"><font style="font-family: 'Times New Roman', serif; font-size: 9pt;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', serif; font-size: 9pt;">Member of our
          Compensation Committee</font></div>
      <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;"><font style="font-family: 'Times New Roman', serif; font-size: 9pt;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', serif; font-size: 9pt;">Member of our Audit
          Committee</font></div>
      <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;"><font style="font-family: 'Times New Roman', serif; font-size: 9pt;">(3)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman', serif; font-size: 9pt;">Member of our
          Nomination and Corporate Governance Committee</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The following are brief biographies of each of the seven (7) director nominees, based upon our records and information furnished to us by them:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Paul Sekhri </font>joined Compugen&#8217;s Board of Directors as its Chairman in October 2017. Paul Sekhri was appointed the President and CEO of
        eGenesis, Inc. in January 2019. Prior to joining eGenesis, Inc, Mr. Sekhri served as President and CEO of Lycera Corp. from February 2015 through December 2018.&#160; From April 2014 through January 2015, Mr. Sekhri served as Senior Vice President,
        Integrated Care for Sanofi. From May 2013 through March 2014, Mr. Sekhri served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries Ltd. Prior to joining Teva, Mr. Sekhri
        spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004 to 2009, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon
        Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and
        Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. Mr. Sekhri&#8217;s first role at
        Novartis was as Global Head, Early Commercial Development. Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in Zoology. Mr. Sekhri is currently a member of the Board
        of Directors of Veeva Systems Inc., Ipsen S.A., Chairman of the Board of Supervisory Directors of Pharming N.V. and Chairman of the Board of Petra Pharma. Additionally, Mr. Sekhri is on the Board of Directors of the TB Alliance, and, as an avid
        classical music enthusiast, is on the Boards of The Metropolitan Opera, The Knights and the English Concert in America. Mr. Sekhri is also an active member of the Patrons Council of Carnegie Hall.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Dr. Anat Cohen-Dayag </font>joined Compugen&#8217;s Board of Directors in February 2014. Dr. Cohen-Dayag joined Compugen in 2002 and held various
        positions. In November 2008, Dr. Cohen-Dayag was appointed as Vice President, Research and Development. In June 2009, Dr. Cohen-Dayag was appointed as co-Chief Executive Officer of Compugen and in March 2010 Dr. Cohen-Dayag was appointed as
        Compugen&#8217;s President and CEO. Prior to joining Compugen, Dr. Cohen-Dayag was head of research and development and member of the Executive Management at Mindsense Biosystems Ltd. Prior to Mindsense Biosystems Ltd., Dr. Cohen-Dayag served as a
        scientist at the R&amp;D department of Orgenics Ltd. Dr. Cohen-Dayag holds a B.Sc. in Biology from the Ben-Gurion University, Israel, and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science,
        Israel.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">7</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Eran Perry </font>joined Compugen&#8217;s Board of Directors in July 2019.&#160; E<font style="background-color: #FFFFFF;">ran Perry brings to Compugen
          over 20 years of diverse experience across various segments of the healthcare industry as an entrepreneur and venture capital investor as well as in general management and strategy. In 2018, Mr.&#160;Perry co-founded MII Fund &amp; Labs, a
          dermatology-focused venture capital fund where he also serves as Managing Director and Chairman of the Investment Committee. Since 2017, Mr. Perry has been a co-founder and active board member of ICD Pharma, a developer of cannabis-based
          pharmaceuticals. Mr. Perry is also the co-founder and board member of several pharmaceutical companies including Musli Thyropeutics, Seanergy Dermatology, and Follicle Pharma. From 2006 to 2016, he served as Managing Director and Partner of
          Israel Healthcare Ventures (&#8220;IHCV&#8221;) and represented IHCV in numerous portfolio companies. Prior to IHCV, Mr. Perry was a consultant in McKinsey &amp; Company, serving clients worldwide in the pharmaceutical industry, among others. Prior to that,
          he was a member of the Global Marketing group at Novartis Oncology.&#160; Before moving to the private sector, Mr.&#160;Perry served in the Israeli Ministry of Justice. Mr. Perry holds an MBA from Columbia University, and an LL.B. in Law and a B.Sc. in
          Mathematics and Computer Science, both from the Tel Aviv University.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Gilead Halevy </font>joined Compugen&#8217;s Board of Directors in June 2018. Mr. Halevy serves as a general partner of Kedma Capital Partners, a
        leading Israeli private equity fund, of which he is also a founding member, since 2006. Prior to establishing Kedma, Mr. Halevy served as a Director at Giza Venture Capital from 2001 to 2006, where he led investments in communication and
        information technology companies and directed Giza&#8217;s European business activities. From 1998 to 2001, Mr. Halevy practiced law at White &amp; Case LLP. Mr. Halevy was also a founding member of the White &amp; Case Israel practice group during that
        time. Mr. Halevy currently serves as chairman of Brand Industries Ltd. (TASE), Iskoor Finance Ltd., Carmel Wineries, Continuity Software Ltd. and as a director of S. AL Holdings. Mr. Halevy holds a B.A. in Humanities (multidisciplinary program for
        exceptional students) and an LL.B. (Magna Cum Laude) both from the Hebrew University of Jerusalem.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Dr. Jean-Pierre Bizzari </font>joined Compugen&#8217;s Board of Directors in September 2018. Dr. Bizzari is a world-renowned oncology expert who
        brings to Compugen over 35 years of broad experience in oncology drug development. Dr. Bizzari served as Executive Vice President and Global Head of Oncology at Celgene Corporation, responsible for Celgene&#8217;s clinical development and
        operations-statistics teams across the United States, Europe and Asia/Japan where he oversaw the development and approval of leading oncology products, including REVLIMID&#174; (lenalidomide), VIDAZA&#174; (azacitidine), ISTODAX&#174; (romidepsin) and ABRAXANE&#174;
        (nab-paclitaxel). In addition, he was chairman of Celgene&#8217;s hematology oncology development committee and a member of the company&#8217;s management committee. Prior to Celgene, Dr. Bizzari was the Vice President, Clinical Oncology Development for
        Sanofi-Aventis (formerly Rh&#244;ne-Poulenc, Rh&#244;ne-Poulenc Rorer and Aventis) where he oversaw the approval of Eloxatin&#174; (oxaliplatin), Taxotere&#174; (docetaxel) and Elitek&#174; (rasburicase). Dr. Bizzari joined the pharmaceutical industry in 1983 as Head of
        Oncology at the Institut de Recherches Internationales SERVIER (France). Dr. Bizzari is a member of the Scientific Advisory Board of the French National Cancer Institute, and a member of the board of the European Organization of Research and
        Treatment of Cancer and Chairman of the New Drug Advisory Committee. He also serves on the boards of Halozyme Therapeutics, Onxeo, Oxford BioTherapeutics, Nordic Nanovector and Transgene. Dr. Bizzari received his medical degree from the Nice
        Medical School and has trained at the Piti&#233;-Salp&#234;tri&#232;re Hospital in Paris, The Ontario Institute for Cancer Research, and The McGill Rosalind and Morris Goodman Cancer Research Centre (formerly the McGill Cancer Center) in Montreal, Canada.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Dr. Kinneret Livnat Savitzky </font>joined Compugen&#8217;s Board of Directors in June 2018. Since October 2017, Dr. Livnat Savitzky served as the
        Interim CEO, since January 2018 as a board member, and since May 2018 also as CEO of FutuRx Ltd., an Israeli biotechnology accelerator established by OrbiMed Israel Partners, Johnson &amp; Johnson Innovation and Takeda Ventures Inc. (the venture
        group of Takeda Pharmaceutical Company). As part of her role at FutuRx she also serves as a chairperson or board member in several of the FutuRx portfolio companies. Dr. Livnat Savitzky also serves on the boards of the following biotechnology or
        healthcare companies: as an active chairperson in KAHR Medical and as a director in Hadasit Medical Research and Development, DreaMed Diabetes and Biomica. In addition, Dr. Livnat Savitzky serves as a consultant to other pharmaceutical development
        companies and related funds. From 2010 to 2016, Dr. Livnat Savitzky served as CEO of BioLineRX Ltd., a Nasdaq-listed drug development company focused on oncology and immunology. During her tenure, BioLineRX signed a strategic collaboration with
        Novartis as well as licensing agreements with Merck (MSD), Genentech and others.&#160; Prior to being appointed CEO of BioLineRX, Dr. Livnat Savitzky held various R&amp;D management positions at BioLineRX and Compugen. Dr. Livnat Savitzky holds a B.Sc.
        in Biology from The Hebrew University of Jerusalem, and an M.S.c and Ph.D. with distinction in Human Genetics from Tel Aviv University.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">8</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 28.1pt; line-height: 1.25;"><font style="font-weight: bold;">Sanford (Sandy) Zweifach </font>joined Compugen&#8217;s Board of Directors in June 2018. Mr. Zweifach is the Founder of Nuvelution Pharma, Inc. and
        since 2015 through 2019 was the Chief Executive Officer of Nuvelution Pharma, Inc. From 2010 to 2015, Mr. Zweifach served as CEO of Ascendancy Healthcare, Inc., which he also founded. He has also been a Partner at Reedland Capital Partners, a
        boutique investment bank, from 2005 to 2010, where he headed its life sciences M&amp;A and advisory efforts. From 2003 to 2005, he was CEO of Pathways Diagnostics, a biomarker development company. Mr. Zweifach was a Managing Director/CFO of Bay
        City Capital, a venture capital/merchant banking firm, specializing in the biotechnology and the life science industry, where he was responsible for oversight of the firm&#8217;s finance department, as well as President of the firm&#8217;s M&amp;A and
        financing division. Prior to this, he was President and CFO of Epoch Biosciences, which was acquired by Nanogen in 2004. Mr. Zweifach currently serves as the Chairman of the Board of Directors of Palladio Biosciences, as an Executive Chairman of
        Janpix, Inc. and as a member of the Board of Directors of IMIDomics, S.L. and Essa Pharma, Inc. Earlier in his career, Mr. Zweifach was a Certified Public Accountant (US) for Coopers &amp; Lybrand and held various investment banking positions
        focusing on biotechnology. He received his B.A. in Biology from UC San Diego and an M.S. in Human Physiology from UC Davis.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Directors&#8217; Compensation</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><u>Compensation to our Non-Executive Directors (other than the chairman of the Board, Mr. Paul Sekhri)</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">As approved by the Company&#8217;s shareholders on August 6, 2018, each of our non-executive directors, whether currently in office or appointed in the future, excluding the chairman
        of the Board (each, a &#8220;<font style="font-weight: bold;">non-executive director</font>&#8221;) is entitled to the following compensation: (a) (i) an annual fee of $45,000&#160;and an additional annual amount for service as a member of each of the Company&#8217;s
        board committees (up to $2,500 for service as a member of a committee and up to $5,000 for service as a chairman of a committee); and (ii) an annual grant of options to purchase Ordinary Shares, with a one-time grant of 35,000 options&#160; in the first
        year of service (the &#8220;<font style="font-weight: bold;">Initial Option Grant</font>&#8221;) and an additional annual grant of 10,000 options in each of the following years of service (the &#8220;<font style="font-weight: bold;">Annual Option Grant</font>&#8221;).
        The&#160;grant date of each Initial Option Grant is the date of appointment for service as director, whether initially appointed by the Board or by the general meeting of shareholders, with an exercise price equal to the closing price of the Ordinary
        Shares on the Nasdaq on the last trading day prior to the date of initial appointment to serve on the Board. The grant date of each Annual Option Grant is such date on which the Board approves the annual option grants to other Office Holders
        (provided that the service as director continues at the time of each grant), and the exercise price equals to the closing price of the Ordinary Shares on the Nasdaq on the last trading day prior to such Board approval. All such grants vest over a
        four-year period as follows: 25% of the options granted vest on the first day of the quarter one calendar year immediately following the quarter in which the options were granted, and an additional 6.25% of the options granted vest each quarter
        thereafter for the next thirty six (36) months. Other than as described herein, both the Initial Option Grants and the Annual Option Grants are subject to the terms and conditions of the Company&#8217;s 2010 Share Incentive Plan (the &#8220;<font style="font-weight: bold;">2010 Plan</font>&#8221;), or any other equity-based incentive plan that the Company may adopt in the future and pursuant to which these options would be granted, and will expire ten years after their grant date, unless they
        expire earlier in accordance with the terms of the 2010 Plan.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">Notwithstanding the terms of the relevant equity-based plan, all options granted to non-executive directors shall become fully vested immediately upon the completion of one or
        more of the following events, whether by way of a consolidation, merger or reorganization of the Company or otherwise: (a) a sale of all or substantially all of Company&#8217;s issued share capital or assets to any other company, entity, person or a
        group of persons, or (b) the acquisition of more than 50% of the Company&#8217;s equity or voting power by any shareholder or group of shareholders. Further, notwithstanding the terms of the relevant equity-based plan, all options granted which shall be
        vested as of the date of final termination of office as a non-executive director of the Company may be exercised within one year following such termination of office. To the extent legally available and applicable, such options will be granted to
        the non-executive directors through a trustee under Section 102 of the Israel Income Tax Ordinance [New Version], 5721-1961 (the &#8220;<font style="font-weight: bold;">Tax Ordinance</font>&#8221;), under the capital gains route.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">In accordance with the above-mentioned terms, our Compensation Committee and Board, in their separate meetings held on July 28, 2020 and July 29, 2020, respectively, resolved
        to grant to each of our non-executive directors, 10,000 options with an exercise price of $14.40.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">In the Meeting we seek shareholder approval for an adjustment to future Annual Option Grants to our non-executive directors; For additional information, please see Item 4
        below.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">9</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><u>Compensation to Mr. Paul Sekhri, the Company&#8217;s Chairman of the Board of Directors, a Non-Executive Director</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">Subject to his re-election for service as director at the Meeting, Mr. Paul Sekhri is entitled to an annual cash fee in the amount of $150,000 for his service as the Company&#8217;s
        non-executive chairman of the Board (with no committee fees).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">In addition, in October 2017 Mr. Sekhri was granted options to purchase 500,000 ordinary shares, out of which 312,500 options are already vested as of the date of this proxy
        statement. These options are subject to the terms and conditions applicable to options granted under the 2010 Plan, and will expire ten years after their grant date, unless they expire earlier in accordance with the terms of the 2010 Plan. The
        acceleration provisions applicable to options granted to other non-executive directors specified above apply to the options granted to Mr. Sekhri. </div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">In the Meeting we seek shareholder approval for an annual equity award plan to our non-executive Chairman of the Board; For additional information, please see Item 4 below.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">For more information relating to the compensation paid to our directors, including insurance coverage, indemnification and exemption, see &#8220;Item 6. Directors, Senior Management
        and Employees - B. Compensation&#8221; in our 2019 Form 20-F.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 4.5pt; line-height: 1.25;">If re-elected, in consideration for their service, our director nominees shall be entitled to the compensation specified herein and as further specified in Items 3 and 4, as
        applicable, to the extent approved by our shareholders in the Meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">It is proposed that the following resolution be adopted at the Meeting:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 17pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font> that each of Mr. Paul Sekhri, Dr. Anat Cohen-Dayag, Mr. Eran Perry, Mr. Gilead Halevy, Dr. Jean-Pierre Bizzari, Dr. Kinneret
        Livnat Savitzky and Mr. Sandy Zweifach be, and he or she is hereby, re-elected to serve as a member of the Board of Directors of the Company <font style="background-color: #FFFFFF;">to hold office until immediately following the Company&#8217;s 2021
          annual general meeting and until his or her respective successor has been elected, or until his or her office </font>is vacated earlier in accordance with the provisions of the Companies Law and the Articles.&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Election of each of the director nominees will be voted upon separately at the Meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-right: 0.3pt; line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">An affirmative vote of a majority of the Ordinary Shares represented and voting on this proposal at the Meeting in person, by proxy or by voting through the Electronic Voting System, is required
        for the approval of the re-election of each of the above director nominees.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">The Board recommends that the shareholders vote &#8220;FOR&#8221; the proposed resolution.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">ITEM NO. 2</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">APPROVAL OF THE AMENDED AND RESTATED COMPENSATION POLICY OF THE </div>
        <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">COMPANY</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Background</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">As required under the Companies Law, the Company maintains a compensation policy that provides a framework for terms of office and employment of our Office Holders, including cash compensation,
        equity awards, severance and other benefits, the grant of an exemption from liability, insurance coverage, and an undertaking to indemnify or indemnification. The Company&#8217;s compensation policy was originally approved by our shareholders on
        September 17, 2013, and amendments were subsequently approved on July 29, 2015, October 19, 2017 and o<font style="background-color: #FFFFFF;">n September 19, 2019, where the only amendment in 2019 was an increase of the annual premium that may be
          paid with respect to our D&amp;O insurance coverage (such compensation policy, as amended, shall be referred to as </font>the &#8220;<font style="font-weight: bold;">Compensation Policy</font>&#8221;). The Companies Law also requires that the Compensation
        Policy be reviewed from time to time by the Compensation Committee and the Board, to consider its adequacy and propose amendments to the extent appropriate or required.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">In the three-year period since our Compensation Policy was last amended and restated in 2017, the Company has significantly evolved and has significantly progressed in many aspects of its
          business, including, among others, a major expansion in the Company&#8217;s clinical stage pipeline and additional collaborations with big pharma (AstraZeneca and Bristol-Myers Squibb), which have made us a bigger enterprise with an increasing global
          presence and with global executives and Board members. The Company&#8217;s business success and effective strategy have contributed to a major increase in the Company&#8217;s market capitalization (from approximately $200 million in July 2017 to
          approximately $1.2 billion in July 2020) which also led to the inclusion of the Company&#8217;s Shares in the Nasdaq Biotechnology Index and the TASE 125 Index, and to an increase in analyst coverage (from two to seven analysts).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">10</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; line-height: 1.25;">To illustrate some of the transformation that the Company has gone through during the three-year period specified above, and the shareholder value created during such period, see the below
          illustration.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25; text-align: center;"> <img width="962" border="0" height="659" src="image00003.jpg"></div>
        <div style="line-height: 1.25"> <br>
        </div>
        <div style="line-height: 1.25;"></div>
        <div style="text-align: justify; line-height: 1.25;">We are now competing with large U.S. and European companies in the biotechnology and pharmaceutical industries. These are fast-paced industries, characterized by aggressive competition over
          talent, becoming more intense over the last couple of years, and resulting in a significant increase in levels of total compensation. Additionally, as compared to other industries, the biotechnology and pharmaceutical fields have not suffered a
          similar downturn due to Covid-19 and may have even become more competitive with respect to talent. As a leading biotechnology company, with several executives residing outside of Israel (in the United States, Europe and Asia), we are required to
          adopt a compensation framework and compensation practices that are in line with those of our peers in order to be competitive. Unlike our U.S. peers, which are comprised of U.S. issuers subject to the &#8220;Say on Pay&#8221; model, we are subject to an
          ex-ante process governed by Israeli legislation, which requires the adoption of a compensation policy that is brought for approval by Company shareholders at least once every three years. Hence, while the &#8220;Say on Pay&#8221; model requires shareholder
          approval of compensation practices in retrospect, Israeli legislation imposes forward looking limitations on the Compensation Committee&#8217;s and the Board&#8217;s authority to approve executive compensation, setting a maximum cap upon each compensation
          component. Should the Compensation Committee and the Board wish to grant executive compensation that exceeds a certain cap defined under the Compensation Policy, it cannot do so without seeking the specific approval of our shareholders in
          advance. Our competitors are not limited in this manner and have the authority to approve executive compensation as they deem is in the best interest of their company. Having the appropriate authority to compete over executive talent in our
          industry is, therefore, of utmost importance, especially considering that there may be significant variance among our executives in terms of individual compensation levels based on their position, location, expertise and experience and our
          compensation policy should provide the Compensation Committee and the Board with authority to approve executive compensation that is competitive in relation to that provided by our peers, both in ordinary and exceptional circumstances.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">In light of all of the above, and in order to determine the global best practices in executive compensation and to ascertain the positioning of our Office Holders&#8217; pay packages vis-&#224;-vis our
          peers, we conducted a benchmarking study with peer companies;&#160;the study, conducted together with an outside consultant, included executive compensation information of comparable companies located in Israel and in the United States, including
          public Israeli companies traded on Nasdaq or dually listed on Nasdaq and TASE, which operate globally in the life science and hi-tech industries, some of which do business in the same geographical locations as the Company (the &#8220;<font style="font-weight: bold;">Peer Group</font>&#8221;). We also evaluated studies by Zviran for local perspective and by Radford for a global perspective, in order to better understand the compensation practices of our domestic and global competitors,
          with whom we compete for talent.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">11</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">Given the Company&#8217;s development and growth in recent years, as detailed above, in light of the need to enhance the global competitiveness of the Company in attracting and retaining highly
          qualified Office Holders worldwide, and considering the results of the benchmarking study, our Committee and Board have concluded that certain changes to our Compensation Policy are required. In addition, as part of the review of the Compensation
          Policy, our Compensation Committee and Board also considered the Company&#8217;s experience gained in implementing the Compensation Policy in previous years, as well as relevant changes that have been made to the Companies Law since the Compensation
          Policy was first adopted.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Accordingly, our Compensation Committee and Board have determined in their separate meetings held on July 28, 2020 and July 29, 2020, respectively, to amend our Compensation Policy and replace it
          with the Amended and Restated Compensation Policy attached to this proxy statement as <font style="font-weight: bold;"><u>Exhibit A</u></font> (the &#8220;<font style="font-weight: bold;">Amended Policy</font>&#8221;).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">We now seek shareholder approval for the Amended Policy.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">General</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">The Amended Policy attached to this Proxy Statement is shown as a &#8220;redline&#8221; against the current Compensation Policy, to reflect all the proposed changes to the current Compensation Policy. The
          main proposed amendments to the current Compensation Policy are as follows (terms and definitions used hereunder are in accordance with the terms and definitions used in the Compensation Policy):</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; text-indent: 10.95pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Section 3.3.1</u> - While no change was actually made to the definition of the Company Objectives, except for extending the enumerated list of Company
          Objectives examples, the Compensation Committee and the Board deemed it advisable to amend the Compensation Policy so that the Corporate Objectives will be enhanced with an additional requirement - that it is comprised of at least two (2)
          measurable criteria. The Compensation Committee and the Board further resolved to amend the minimum weight of the Company Objectives (from 40% to 30%) and the maximum weight of the Individual Objectives (from 45% to 55%) for Office Holders that
          are not our Chief Executive Officer or directors, as in certain cases it better serves the Company&#8217;s interest to be able to provide a more significant incentive with respect to the Individual Objectives and specific KPIs for these individuals.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In accordance with an amendment to the Companies Law allowing chief executive officers to receive a non-material portion (i.e., up to three monthly base salaries) as a
          discretionary payment without the need to seek shareholder approval (if permitted under the compensation policy), and in line with the practice of the Peer Group, the Compensation Committee and the Board resolved to include in the Amended Policy
          the authority to determine that the discretionary portion of the CEO Annual Target Cash Bonus may be up to three monthly base salaries, while the current Compensation Policy provides for up to 20% of such Annual Target Cash Bonus (which reflects
          1.8 monthly base salaries based on Annual Target Cash Bonus).</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; text-indent: 10.95pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Section 3.4</u> - While our existing Compensation Policy does not specify the exercise price pursuant to which we will issue options, our Compensation
          Committee and Board determined that it is in the Company&#8217;s interest, and in line with the Company&#8217;s practice, to include under the Amended Policy the following commitments to our shareholders:</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(i) to issue options with an exercise price which shall be at least our Share&#8217;s fair market value; and</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(ii) not to effect, without first obtaining shareholder approval, any repricing of equity awards granted to our Office Holders.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Furthermore, today, the maximum limits for executive equity awards permitted under our Compensation Policy are a function of each officer&#8217;s individual base salary. Based on the
          high volatility in the price of our Shares, setting a limit which is value-based, can lead to circumstances where the cap reflects a highly variable number of options that can be issued. However, setting the equity-based award cap based on a
          dilution threshold is aligned with the Company&#8217;s performance and needs - it allows the Company to create a proper incentive by granting equity awards that are not tied to the base salaries, inherently adapts the value of the awards granted to the
          market capitalization of the Company at the time of grant and creates strong accountability for the Company&#8217;s executives, allowing the value of the awards to grow as the Company&#8217;s value grows, but to also decrease if the Company&#8217;s value
          decreases. Therefore, the Compensation Committee and the Board deemed it advisable to amend our annual equity-based award cap from the current arrangement, which is based on 300% of the annual base salary, to a dilution based evaluation of the
          award on the date of grant, so that (i) if only options are granted, the portion of the annual grant of options that is scheduled to vest in any year following the grant date shall not exceed 0.06% of the issued and outstanding share capital of
          the Company on the date of grant; (ii) if only RSUs or other equity awards which are not options (&#8220;<font style="font-weight: bold;">Other Equity</font>) are granted,&#160;the portion of such annual grant that is scheduled to vest in any year following
          the grant date shall be&#160;reduced by 50%&#160;(i.e., 0.03% of the issued and outstanding share capital of the Company on the date of grant), and (iii) with respect to an annual grant that combines both types of equity awards (i.e. options and Other
          Equity), the portion of such annual grant that is scheduled to vest in any year following the grant date shall be calculated, on a&#160;pro rata&#160;basis, to give effect to the relative portion of each type of equity award.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">12</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Compensation Committee and Board further proposed that the equity award cap will also include an absolute upper limit set at a Company market capitalization of US$3
          billion. Accordingly, in the event that the Company&#8217;s market capitalization exceeds US$3 billion, the dilution limit of the equity awards will be adjusted proportionally downwards to reflect the value limit corresponding to such market
          capitalization limitation.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, in order to further strengthen the Company&#8217;s emphasis on performance and in alignment with the long-term goals and strategy of the Company, our Compensation
          Committee and Board deemed it advisable to amend the Compensation Policy by setting the following additional commitments to our shareholders with respect to equity-based compensation:</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(i) to assure that at least 30% of the value of any annual grant of options or Other Equity to our Office Holders, will be performance-based, so that such 30% shall be either
          based on options subject to time-based vesting or on Other Equity which include performance-based vesting criteria to be determined by the Compensation Committee and Board, unless the total value of the annual award is lower than US$100,000; and</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(ii) to add a provision under the Compensation Policy, whereby the employment terms of future executive officers who join the Company shall include a &#8220;double trigger&#8221;
          acceleration mechanism.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">It should be noted that during the time that we maintain a compensation policy, our Compensation Committee and our Board have used their authority in granting equity awards in
          a very conservative manner, strongly stressing accountability by awarding our executives with options at market price, in numbers and value which were well below the limits provided in the current Compensation Policy. As of July 31, 2020,
          following the annual options grant for 2020, the total number of outstanding options amounted to 6,338,105, which options constitute approximately 7.0% of our issued and outstanding share capital on a fully diluted basis as of such date (assuming
          the exercise of all outstanding options and warrants granted by the Company).&#160;The Company has significantly reduced its outstanding equity overhang since last year and will continue to take a disciplined approach in managing the long-term effects
          of equity incentive grants as it is committed to a vigilant management of dilution.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; text-indent: 10.95pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Section 4B</u> - In line with the approval of our shareholders on August 6, 2018 to issue an initial grant of 35,000 options to each of our non-executive
          directors (excluding the chairman of the Board), in view of the Peer Group information and considering that any issuance exceeding 35,000 options to each of our non-executive directors (excluding the chairman of the Board) as an initial grant
          will require shareholder approval under the Companies Law, the Compensation Committee and the Board deemed it advisable to amend the limitation that applies to initial grants of equity to non-foreign directors and allowed the same amount of
          initial option grant to all directors.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; text-indent: 10.95pt; line-height: 1.25;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Section 5</u> - Our Compensation Policy provides, among other things, that we may purchase and periodically renew, at our expense, insurance coverage in
          respect of the liability of our current and future Office Holders, to the maximum extent permitted by law, of up to US$50 million, with a maximum annual premium of up to US$900,000, subject to certain adjustments. Due to a major increase in our
          market capitalization, as detailed above, our Compensation Committee and our Board deemed it advisable to increase our maximum coverage to up to US$100 million.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Furthermore, the increased number of lawsuits filed against U.S. listed companies, specifically securities law class actions, and significant payments made recently by
          insurance companies to settle such claims and actions have caused (i) fewer insurance companies to offer D&amp;O insurance for Israeli U.S. listed companies, and (ii) a significant increase in the premiums paid for such policies market-wide,
          which has resulted in the premium limitations set under the current Compensation Policy becoming inadequate.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In order to allow the Company to purchase appropriate D&amp;O insurance coverage, our Compensation Committee and Board have approved to amend the Compensation Policy so that the
        premium for such policies shall be based on applicable market terms for the coverage sought by the Company and provided such coverage is within the coverage amount permitted under the Companion Policy, without setting a defined amount, and provided
        that such premium does <font style="background-color: #FFFFFF;">not have a substantial effect on the Company&#8217;s profitability, assets or obligations. Otherwise, shareholder approval will need to be obtained. It is noted that the above amendment is
          also in compliance with the terms set under a recent staff bulletin issued by the ISA, which indicates that an approval of D&amp;O insurance pursuant to a company&#8217;s compensation policy does not require setting defined premium caps within the
          Compensation Policy, if premium levels are determined in accordance with market terms, and do not have a material impact on the profitability, assets or obligations of the Company. Such staff bulletin also acknowledges the importance of retaining
          and attracting skilled and experienced directors and acknowledges that the premium is derived from market conditions and that in some cases the Company itself is the main beneficiary.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">13</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">Based on all of the foregoing, the Compensation Committee and the Board resolved to approve, and to recommend that shareholders approve, the Amended Policy.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">If the Amended Policy is approved by our shareholders, then the date of such amendment shall be deemed to be the date of the adoption of the Amended Policy in its entirety, so that the Amended
          Policy shall be in full force and effect for a period of three (3) years thereafter. If the Amended Policy is not approved by our shareholders, then the current Compensation Policy shall continue to be in full force and effect for the duration of
          the three-year period that commenced on October 19, 2017, the date it was last approved by our shareholders.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">It is proposed that the following resolution be adopted at the Meeting:</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; margin-left: 21.3pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font> that the Amended Policy in the form attached hereto as <font style="font-weight: bold;"><u>Exhibit A</u></font> be, and
          hereby is, approved and adopted&#8221;.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="margin-right: 0.3pt; line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 0.3pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the Ordinary Shares represented and voting on this proposal at the Meeting in person, by proxy or by electronic voting is
        required for the approval and adoption of the Amended Policy; provided that, the majority of the shares voted in favor of this proposal are not held by &#8220;controlling shareholders&#8221; or shareholders with &#8220;personal interest&#8221; in the approval of such
        proposal, not taking into account any abstention, or that the total number of shares referred to above voted against this proposal, does not exceed two (2) percent of the aggregate voting rights in the Company.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 0.3pt; line-height: 1.25;">Under the Companies Law, in general, a person will be deemed to be a controlling shareholder if that person has the power to direct the activities of the company, otherwise
        than by reason of being a director or other office holder, and a person is deemed to have a personal interest if any member of the shareholder&#8217;s immediate family, or the immediate family of a shareholder (spouse, sibling, parent, grandparent or
        each of the foregoing with respect to shareholder&#8217;s spouse)&#160;has a personal interest in the adoption of the proposal. In addition, shareholder is deemed to have a personal interest if a company that is affiliated with the shareholder, other than
        Compugen, has a personal interest in the adoption of the proposal. Such company is a company in which a shareholder or a member of shareholder&#8217;s immediate family serves as a director or chief executive officer, has the right to appoint a director
        or the chief executive officer, or owns 5% or more of the outstanding shares. However, shareholder is not deemed to have a personal interest in the adoption of the proposal if the shareholder&#8217;s interest in such proposal arises solely from
        shareholder&#8217;s ownership of our shares, or from a matter that is not related to a relationship with a controlling shareholder.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 0.3pt; line-height: 1.25;"><font style="font-weight: bold;">Please note that we consider it highly unlikely that any of our shareholders is a controlling shareholder or has a personal interest in this
          proposal</font>. However, as required under Israeli law, the enclosed form of proxy requires that you specifically indicate whether you are, or are not, a controlling shareholder or have a personal interest in this proposal. Without indicating to
        this effect, we will not be able to count your vote with respect to this proposal.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">The Board recommends that the shareholders vote &#8220;FOR&#8221; the proposed resolution.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">ITEM NO. 3</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPENSATION TO THE COMPANY&#8217;S CHIEF EXECUTIVE OFFICER</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">A SALARY INCREASE; A SPECIAL CASH BONUS; AN ANNUAL CASH BONUS PLAN AND </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">AN ANNUAL EQUITY AWARD PLAN</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Background; Chief Executive Officer&#8217;s Current Terms of Employment</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, arrangements regarding the compensation of a chief executive officer of a publicly traded company require approvals of the compensation committee, board of directors and
          company&#8217;s shareholders by a special majority vote (as set forth below), in that order. </div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Pursuant to Dr. Anat Cohen-Dayag&#8217;s employment agreement, she is entitled to a gross monthly base salary of NIS 118,800 (approximately $33,850 according to the average $/NIS representative exchange
        between January 1, 2020 and June 30, 2020 which is $1=NIS3.5092, the &#8220;<font style="font-weight: bold;">Representative Rate</font>&#8221;), as approved by our shareholders in the 2015 annual general meeting. Dr. Cohen-Dayag is also entitled to certain
        benefits and perquisites customary in Israel, including those mandated by applicable law. In addition, Dr. Anat Cohen-Dayag is eligible for an annual cash bonus based upon achievement of objectives determined by the Company and to an annual grant
        of equity pursuant to her equity award plan.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">14</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">On August 6, 2018, our shareholders approved that Dr. Cohen-Dayag shall be eligible to receive an annual target bonus payment of up to six (6) monthly base salaries and an annual maximum bonus
          payment of up to nine (9) monthly base salaries for each of calendar years 2018, 2019 and 2020, without the need for further shareholder approval, subject to meeting the specific performance criteria approved by the shareholders and as further
          determined by the Compensation Committee and Board with respect to each such year, provided that she continues to be employed as the Company&#8217;s Chief Executive Officer through the last day of the calendar year with respect to which the annual cash
          bonus is paid.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">In accordance with such approval, for 2018 and 2019, Dr. Cohen-Dayag received an annual cash bonus payment of NIS 555,984 and NIS 498,960, respectively (approximately $158,400, and $142,200,
          based on the Representative Rate), after meeting the specific performance criteria set with respect to each such year.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Additionally, on August 6, 2018, our shareholders approved an annual equity award plan for Dr. Cohen-Dayag for each of the calendar years 2018, 2019 and 2020, according to which Dr. Cohen-Dayag
          shall be granted options to purchase up to 150,000 Ordinary Shares in each of 2018, 2019 and 2020, as shall be determined by the Compensation Committee and Board with respect to each such year. In order to align such grants (including the
          exercise price and vesting period thereof) with the annual grant of options to other executive Office Holders (for whom shareholder approval is not required), our shareholders resolved that the annual grant to Dr. Cohen-Dayag will be made on such
          date in 2018, 2019 and 2020 on which the Board approves the respective year&#8217;s annual option grants to other Office Holders.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">According to such annual equity award plan, on July 31, 2018, Dr. Cohen-Dayag was granted with 120,000 options with an exercise price of $3.15. In 2019 Dr. Cohen-Dayag was granted with a total of
          150,000 options, of which 120,000 options were granted on March 19, 2019 with an exercise price of $3.80, and 30,000 options were granted on August 1, 2019 with an exercise price of $3.24. On July 29, 2020, Dr. Cohen-Dayag was granted with
          150,000 options, with an exercise price of $14.40. The Compensation Committee and the Board confirmed that each such option grant complied with the Compensation Policy.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">The options granted in each respective year are subject to the terms and conditions of the 2010 Plan. Each annual option grant vests over a four-year period as follows: 25% vests on the first day
          of the quarter one calendar year immediately following the quarter in which the options are granted and an additional 6.25% vests each quarter thereafter for the next thirty six (36) months. These options have an exercise price equal to the
          closing price of the Company&#8217;s ordinary shares on the Nasdaq on the last trading day prior to the day of approval of each grant by the Board, and they expire ten (10) years after their grant date, or earlier in accordance with the terms of the
          2010 Plan or the terms of the option agreements entered into between the Company and Dr. Cohen-Dayag. The options are granted through a trustee under Section 102 of the Tax Ordinance (Capital Gains Route).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Dr. Cohen-Dayag&#8217;s employment agreement may generally be terminated by either party by providing six (6) months advance written notice, provided that in the event of termination by the Company for
          &#8220;justifiable cause&#8221; (as such term is defined in her employment agreement as shall be in effect from time to time) the Company may terminate Dr. Cohen-Dayag&#8217;s employment without advance notice and that Dr. Cohen-Dayag may resign with advance
          notice of only two (2) months in the event of resignation for &#8220;good reason&#8221; (as such term is defined in her employment agreement as shall be in effect from time to time). Upon termination, Dr. Anat Cohen-Dayag will be entitled to receive certain
          payments associated with termination.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">In the event that Dr. Cohen-Dayag&#8217;s employment is (a) terminated by the Company, other than for &#8220;justifiable cause&#8221;; or (b) terminated by Dr. Cohen-Dayag for &#8220;good reason&#8221; (hereinafter, (a) and
          (b) shall be referred to together as &#8220;<font style="font-weight: bold;">Dismissal</font>&#8221;), Dr. Cohen-Dayag will be entitled to a one-time payment equal to six (6) monthly base salaries (the &#8220;<font style="font-weight: bold;">Termination Payment</font>&#8221;),






          and upon Dismissal within one (1) year following certain &#8220;change of control&#8221; events (as defined in her employment agreement as shall be in effect from time to time), Dr. Cohen-Dayag will be entitled to a special termination payment (in addition
          to the Termination Payment) in an amount equal to six (6) monthly base salaries.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">In addition, upon Dismissal, or in the event of a &#8220;change of control&#8221;, all outstanding unvested options granted to Dr. Cohen-Dayag as of such time will be accelerated and become immediately
          exercisable as of the effective date of such Dismissal or change of control. Upon Dismissal, Dr. Cohen-Dayag will also be entitled to exercise all outstanding vested options (including those options vested as a result of such accelerated vesting)
          for a period of one (1) year from the date of such Dismissal, provided that such period does not extend beyond ten (10) years from the date of grant. Upon an event of change of control, following which Dr. Cohen-Dayag&#8217;s employment, within twelve
          (12) months of the closing of such an event, is: (a) terminated by the Company, other than for &#8220;justifiable cause&#8221;; or (b) terminated by Dr. Cohen-Dayag for any reason, Dr. Cohen-Dayag will be entitled to exercise all outstanding vested options
          (including those options vested as a result of such accelerated vesting) for a period of one (1) year from the date of termination of her employment, provided that such period does not extend beyond ten (10) years from the date of grant.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">15</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; line-height: 1.25;">Dr. Cohen-Dayag is not entitled to any compensation, including in connection with her role as a director, in addition to that being paid to her as the Chief Executive Officer of the Company.
          However, in the event of termination of Dr. Cohen-Dayag employment agreement, she will be entitled to receive such compensation to the extent and for as long as she will serve as a non-executive director of the Company.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">As of July 31, 2020, the total Number of Ordinary Shares Beneficially Owned (as such term is defined in the beneficial ownership table above) by Dr. Cohen-Dayag&#8217;s is below 1%.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">We now seek shareholder approval for a salary increase, a grant of a special cash bonus, an annual cash bonus plan and an annual equity award plan as specified below to Dr. Anat Cohen-Dayag, our
          Chief Executive Officer, following approval of such compensation items by our Compensation Committee and Board in their separate meetings held on July 28, 2020 and July 29, 2020, respectively.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Salary Increase</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Our Compensation Committee and the Board have resolved to approve, subject to the approval of our shareholders, an adjustment to the gross monthly base salary paid to Dr. Cohen-Dayag in her
          position as the Company&#8217;s Chief Executive Officer, so that her gross monthly base salary will be increased to <font style="font-weight: bold;">NIS 134,125</font> (approximately $38,220 according to the Representative Rate), effective as of March
          1, 2020, reflecting an increase of approximately 2% per year over the last five (5) years.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">When approving the above-mentioned adjustment to the base salary of our Chief Executive Officer, our Compensation Committee and Board of Directors have considered that Dr. Cohen-Dayag has been
          with the Company since 2002 holding various positions, including Vice President - Research and Development, co-Chief Executive Officer and since March 2010, Chief Executive Officer. Dr. Cohen-Dayag has led the Company in its efforts to develop
          and execute its new long-term strategy of transforming from a discovery infrastructure company to a product-oriented discovery and drug development company, focused in the field of cancer immunotherapy, transitioning to a clinical stage
          therapeutic company with its own innovative clinical stage pipeline, and with a global business presence. The Compensation Committee and Board also took into consideration the Company&#8217;s achievements under Dr. Cohen-Dayag&#8217;s leadership, the scope
          of her responsibilities, the business challenges she faces, her experience and qualifications and the significant growth and positive development experienced by the Company since Dr. Cohen-Dayag&#8217;s last compensation review, in terms of clinical
          development, corporate achievements and market value. Further, the members of our Compensation Committee and Board noted the fact that her salary as Chief Executive Officer was last adjusted in January 2015, and also examined the compensation
          paid to other chief executive officers within our Peer Group, which showed that the monthly base salary proposed for Dr. Cohen-Dayag in her position as the Company&#8217;s Chief Executive Officer, is within the average of the Peer Group. The
          Compensation Committee and Board also reviewed the compensation provided to other executives of the Company, as well as other relevant information and materials presented to them. They have analyzed all relevant factors and considerations
          required under our Compensation Policy and the Companies Law, including the responsibilities and duties of Dr. Cohen-Dayag in her position as the Company&#8217;s Chief Executive Officer, the importance of providing competitive compensation to retain
          the most talented and essential employees such as Dr. Cohen-Dayag,<font style="background-color: #FFFFFF;">&#160;</font>Dr. Cohen-Dayag&#8217;s expected contribution and her importance to the future growth of the Company and its pursuit of significantly
          enhancing its business and growth opportunities (collectively, the &#8220;<font style="font-weight: bold;">Compensation Committee and Board Considerations</font>&#8221;).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">The proposed increase in the gross monthly base salary of Dr. Cohen-Dayag in her position as the Company&#8217;s Chief Executive Officer is consistent with the Compensation Policy.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Special Cash Bonus</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">According to our Compensation Policy, in addition to the annual cash bonus, our Compensation Committee and Board may approve a special bonus for significant or extraordinary achievements or efforts
        that produced an exceptional result. The maximum value of the total special bonuses payable to an executive officer with respect to any calendar year shall not exceed six (6) monthly base salaries of the relevant officer.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Upon review of the Company&#8217;s performance during 2019 and Dr. Cohen-Dayag&#8217;s specific contribution thereto, including without limitation: (i) the expansion of the Company&#8217;s clinical-stage pipeline;
        (ii) the major clinical studies progress and presentation of initial clinical data which contributed to the major increase in Company&#8217;s value and positioning; and (iii) the additional funds raised through the Company&#8217;s ATM facility, as well as Dr.
        Cohen-Dayag&#8217;s major contribution to the successful public offering in March 2020 and major role in the Company&#8217;s pursuit of significantly enhancing its business and growth opportunities, the Compensation Committee and the Board determined that it
        is appropriate to grant Dr. Cohen-Dayag, our Chief Executive Officer, a special cash bonus for these achievements.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">16</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">After taking into account all the above-mentioned factors, and all factors and considerations required under the Compensation Policy and the Companies Law, the Compensation Committee and the Board
        approved and are recommending that the shareholders approve, the grant of a special cash bonus to Dr. Anat Cohen-Dayag, in the amount of <font style="font-weight: bold;">NIS 395,840</font> (approximately $112,800 based on the Representative Rate)
        payable to her following the date of the Meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">The proposed grant of a special cash bonus to Dr. Cohen-Dayag is consistent with the Compensation Policy.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Annual Cash Bonus Plan through 2023 (inclusive)</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">As part of the Company&#8217;s forward-looking strategic plans, our Compensation Committee and Board believe that it is appropriate to create for Dr. Cohen-Dayag, our Chief Executive Officer, an annual
          cash bonus plan structure that awards annual achievements and that is aligned with the Company&#8217;s forward-looking strategy. The terms of Dr. Cohen-Dayag&#8217;s annual cash bonus plan for the years 2018, 2019 and 2020 are described above. With the
          upcoming expiration of the existing annual cash bonus plan, our Compensation Committee and Board wish to set an annual cash bonus plan for Dr. Cohen-Dayag for the years 2021, 2022 and 2023. Such annual cash bonus plan shall include annual
          measurable objectives that will be set in advance for any of the said years by our Compensation Committee and Board from a list of approved objectives (specified below) and may also include discretionary components. The Compensation Committee and
          the Board will determine, with respect to each of the relevant years, the target and maximum annual cash bonus, as well as the related objectives and their related weights, including applicable thresholds, and the formula for calculating the
          annual cash bonus payment to be granted to Dr. Cohen-Dayag, all in accordance with the guidelines set forth below. The Compensation Committee and the Board believe that disclosure of the specific objectives set for the annual cash bonus and their
          score, may adversely affect the Company, as such objectives are based on very sensitive business information of the Company and on its strategic plans.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">Target, Maximum Annual Cash Bonus and Eligibility; </font>The annual cash bonus amount that Dr. Cohen-Dayag will be entitled to upon achievement of 100% of her
          objectives, as shall be determined by the Compensation Committee and Board for each of the relevant years, <font style="font-style: italic;">i.e.</font>, her target annual cash bonus, will be up to six (6) monthly base salaries. For each
          relevant year, the annual cash bonus formula will include an over achievement opportunity designed to encourage her to reach exceptional achievements, pursuant to which the maximum payment with respect to each calendar year shall be 150% of the
          target bonus determined by the Compensation Committee and the Board for such year (<font style="font-style: italic;">i.e.</font>, nine (9) monthly base salaries if the target bonus is set at six (6) monthly base salaries). This proposed annual
          target cash bonus and the maximum payment bonus remain the same as under Dr. Cohen-Dayag&#8217;s current bonus plan (<font style="font-style: italic;">i.e.</font>, six (6) and nine (9) monthly base salaries, respectively), and the actual payments will
          be determined linearly based on her performance score for each year. It is noted that the proposed bonus plan sets a target annual bonus at up to six (6) monthly base salaries, while the Amended Policy allows for nine (9) monthly base salaries
          (and thirteen and a half (13.5) monthly base salaries in case of over achievement).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">If less than 50% of the applicable measurable objectives set for a respective year are achieved, Dr. Cohen-Dayag will not be entitled to any annual cash bonus for such year.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Dr. Cohen-Dayag shall be eligible to receive the annual cash bonus for each of the years 2021, 2022 and 2023 under the framework set forth herein, subject to her continuous employment as the
          Company&#8217;s Chief Executive Officer through the last day of the calendar year with respect to which the annual cash bonus is to be paid.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">Objectives; </font>The objectives and weights of the annual cash bonus of Dr. Cohen-Dayag for each of the calendar years 2021, 2022 and 2023 shall be determined
          in advance by the Compensation Committee and the Board for each year, pursuant to the following guidelines:</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="zbedf6423021e4f32a3764d282369dce5">

          <tr>
            <td style="width: 13.28%; vertical-align: top; background-color: rgb(217, 217, 217); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 23.07%; vertical-align: top; background-color: rgb(217, 217, 217); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Weight</div>
            </td>
            <td style="width: 63.65%; vertical-align: top; background-color: rgb(217, 217, 217); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Objectives</div>
            </td>
          </tr>
          <tr>
            <td style="width: 13.28%; vertical-align: top; background-color: rgb(217, 217, 217); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Measurable Objectives</div>
            </td>
            <td style="width: 23.07%; vertical-align: top; background-color: rgb(217, 217, 217); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">80%-100%*</div>
            </td>
            <td style="width: 63.65%; vertical-align: top; background-color: rgb(217, 217, 217); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">For any calendar year, the Compensation Committee and the Board will set at least two (2) measurable criteria and the relative weight of each
                criterion. These measurable criteria may include, <font style="font-style: italic;">inter alia</font>, significant objectives relating to the progress of clinical trials, progress of pipeline products, operational, financial and business
                targets and any additional significant objectives determined by the Compensation Committee and the Board derived from the Company&#8217;s annual work plan and strategy.</div>
            </td>
          </tr>
          <tr>
            <td colspan="3" style="width: 100%; vertical-align: top; background-color: rgb(217, 217, 217); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 13.28%; vertical-align: top; background-color: rgb(217, 217, 217); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Non-measurable Objectives</div>
            </td>
            <td style="width: 23.07%; vertical-align: top; background-color: rgb(217, 217, 217); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Up to three (3) monthly base salaries</div>
            </td>
            <td style="width: 63.65%; vertical-align: top; background-color: rgb(217, 217, 217); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Non-measurable components</div>
            </td>
          </tr>

      </table>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 27pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">* Notwithstanding the said percentage and in compliance with the Companies Law, the Compensation Committee and the Board
          of Directors may determine with respect to our Chief Executive Officer that up to three (3) monthly base salaries will be based on non-measurable criteria as determined herein.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">17</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Our Compensation Committee and Board believe that the proposed annual cash bonus targets and respective maximum bonus payments reflect an appropriate level of cash compensation incentive for our
        Chief Executive Officer, considering the benchmark information relating to the value of the annual cash bonus and taking into account her expertise, experience, value and importance to the Company and its future plans, success, growth and
        profitability, as well as relevant changes in the Companies Law since the Compensation Policy was first adopted. It also suitably links between pay and performance and aligns Dr. Cohen-Dayag&#8217;s interests with those of the Company and its
        shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">When considering the proposed annual cash bonus plan to our Chief Executive Officer, the Compensation Committee and Board took into account numerous factors, including the Compensation Committee
        and Board Considerations. With respect to comparable benchmark information, the data of our Peer Group showed that the annual cash bonus target proposed to Dr. Cohen-Dayag is within the average of the Peer Group and the maximum annual cash bonus
        payment is within the 60<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> percentile of the Peer Group.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Subject to receipt of shareholder approval to the annual cash bonus plan, the Compensation Committee and the Board will determine, subject to the terms herein, without the need for further
        shareholder approval, the actual annual cash bonus payments to be paid, if any, to Dr. Cohen-Dayag, for each of the years 2021, 2022 and 2023.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25;">The proposed annual cash bonus plan for Dr. Cohen-Dayag is consistent with the Amended Policy.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Annual Equity Award Plan through 2023 (inclusive)</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">As part of the Company&#8217;s forward-looking strategic plans, our Compensation Committee and Board believe that it is appropriate to set an annual equity award plan for our Chief Executive Officer
          that is aligned with the Company&#8217;s forward-looking strategy. The terms of Dr. Cohen-Dayag&#8217;s annual equity award plan for the years 2018, 2019 and 2020 are described above. With the upcoming expiration of the existing annual equity award plan, our
          Compensation Committee and Board wish to set an annual equity award plan for Dr. Cohen-Dayag for the years 2021, 2022 and 2023.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Accordingly, and in line with the limitations set forth in our Amended Policy with respect to equity-based compensation, it is proposed to approve an annual equity award plan for the Company&#8217;s
          Chief Executive Officer pursuant to which Dr. Cohen-Dayag shall be granted options to purchase <font style="font-weight: bold;">up to 150,000</font> Ordinary Shares for each of the calendar years 2021, 2022 and 2023 (the &#8220;<font style="font-weight: bold;">Equity Framework</font>&#8221;), as shall be determined by the Compensation Committee and the Board with respect to each calendar year. The Compensation Committee and the Board may nevertheless determine that as part of an
          annual equity grant, they wish to issue <font style="font-weight: bold;">Other Equity</font>. For the purpose of demining the applicability of the Equity Framework to Other Equity, Other Equity shall be given a &#8220;double weight&#8221; relative to
          options, so that each unit of Other Equity will be equal to two (2) option units. For illustration purposes, if the Compensation Committee and Board approve an annual equity grant to Dr. Cohen-Dayag of 40,000 options and 30,000 RSUs, then for the
          purpose of determining whether such grant is within the Equity Framework, the 30,000 RSUs will be given a weight of 60,000 units and the 40,000 options will be counted as 40,000 units, comprising an aggregate of 100,000 units which is within the
          Equity Framework. In any event, at least 30% of the value of any annual equity award to Dr. Cohen-Dayag shall be based on either (i) options granted with fair market value exercise price; or (ii) Other Equity which vesting is based on both time
          and performance criteria, as may be determined by the Compensation Committee and Board.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Additionally, the Equity Framework shall be subject to any additional limitation set in the Amended Policy (including the Annual Threshold therein).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">The value of the maximum award permitted under the suggested Equity Framework, made in options, calculated based on the price of our Ordinary Share on July 29, 2020, is approximately $270,000 for
          each of the years upon which it would vest, assuming a four-year vesting period. For assumptions and key variables used in the calculation of the equity value, please see Note 2m to our 2019 Form 20-F.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">18</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; line-height: 1.25;">It is noted that the maximum amount of equity awards that may be awarded to Dr. Cohen-Dayag under the proposed equity plan, in any year, is equal to the number of options actually granted to her
          in 2019 and in 2020, however, due to the material increase in the Company&#8217;s share price during the last 12-month period, the value of such options as of the date hereof (based on the assumptions and key variables used specified in Note 2m to our
          2019 Form 20-F) is considerably higher than the value of previous years&#8217; grants as of the date of their respective grant. Nevertheless, in approving the option grant for 2020 and the proposed equity award plan for the next three (3) years, our
          Compensation Committee and Board of Directors considered such grant and plan to be in alignment with the Peer Group information, looking both at the equity award value and at the total compensation of our CEO, and with our CEO&#8217;s contribution to
          the Company&#8217;s extraordinary performance, achievements and progress made over the last three (3) years, including the major progress in the Company&#8217;s clinical stage pipeline, the major increase in cash and the major increase in the Company&#8217;s share
          price, which more than quadrupled in the last 12-month period.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">In order to align such equity grants and their terms (including the exercise price of the options and the vesting periods) with the annual grants of equity to employees and other Office Holders
          for whom shareholder approval is not required, the annual equity awards to Dr. Cohen-Dayag under the Equity Framework will be approved by the Board on the date on which it approves the respective year&#8217;s annual equity grants to other Office
          Holders.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Each annual equity grant awarded under the Equity Framework will vest over a four-year period as follows: 25% will vest on the last day of the quarter one (1) year from the date of grant and an
        additional 6.25% will vest on the last day of each quarter thereafter for the next thirty six (36) months.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The options granted under the Equity Framework will have an exercise price equal to the closing price of the Company&#8217;s shares on Nasdaq on the last trading day prior to the approval of each year&#8217;s
        grant by the Board.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The options and Other Equity granted each year to Dr. Cohen-Dayag will generally expire 10 (ten) years after their grant date and shall be subject to the terms and conditions of the 2010 Plan, or
        any other equity-based incentive plan that the Company may adopt in the future and pursuant to which these equity awards would be granted, and to the terms of the agreements/notices for the grant of such options/equity awards signed between the
        Company and Dr. Cohen-Dayag. If applicable, these equity awards will be granted through a trustee under Section 102 of the Tax Ordinance (Capital Gains Route).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">Unless otherwise stated herein, all provisions applicable to the options previously granted to Dr. Anat Cohen-Dayag as specified above (see under <font style="font-weight: bold;">Background;
            CEO&#8217;s Current Terms of Employment</font>)<font style="font-weight: bold;">&#160;</font>shall apply to all options and Other Equity granted to her pursuant to this Item, <font style="font-style: italic;">mutatis mutandis</font>, provided that all
          vested options and Other Equity (to the extent applicable) granted to Dr. Cohen-Dayag under the Equity Framework shall have a one-year exercise term following the termination of her employment as the Company&#8217;s Chief Executive Officer, other than
          in the event of termination for &#8220;cause&#8221; (as defined in her employment agreement as shall be in effect from time to time); The Compensation Committee and Board deemed it advisable to offer an extended exercise period of one-year for vested options
          and Other Equity granted to Dr. Cohen-Dayag under this Item in order to offer Dr. Cohen-Dayag, who is an insider of the Company, a fair opportunity to exercise her vested options and Other Equity (to the extent applicable) after she ceases to
          hold any material non-public information.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">In addition to the foregoing, and not as part of the Equity Framework, Dr. Anat Cohen-Dayag will be entitled to participate in any employee share purchase plan(s) that may be adopted by the
          Company from time to time after the Meeting and until the end of 2023, as long as the fair market value of the benefit provided to her under such employee share purchase plan(s) (determined by the Company at the beginning of the respective
          offering period) in any given twelve (12) month period does not exceed ten percent (10%) of her annual base salary.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">When considering the proposed annual equity award plan to our Chief Executive Officer, the Compensation Committee and Board of Directors took into account numerous factors, including the
        Compensation Committee and Board Considerations, and the considerations set forth in the Compensation Policy.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">When considering comparable industry data and data of our Peer Group, the members of our Compensation Committee and Board noted that the proposed annual equity award plan is within the average of
        the Peer Group, based on the Company&#8217;s price per share as of July 28, 2020. In addition, the Compensation Committee and Board determined that the proposed Equity Framework suitably links pay to performance, aligns our Chief Executive Officer&#8217;s
        interests with those of the Company and its shareholders over the long term and encourages balanced risk management, taking into account that the value of the cap set under the proposed equity plan is tied to the Company&#8217;s share price, so in case
        the share price decreases after its considerable increase in the last year, the potential value of the equity award will proportionately decrease as well.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">Current Status of Equity Holding; </font>As of July 31, 2020, Dr. Cohen-Dayag holds options to purchase a total of 1,100,000 Ordinary Shares, of which options to
        purchase 150,000 Ordinary Shares were granted on July 29, 2020. Out of the options to purchase 1,100,000 Ordinary Shares: (i) options to purchase 732,500 Ordinary Shares, with a weighted average exercise price of $5.48 per share, were exercisable
        as of July 31, 2020 (including options vested within 60 days of this date); and (ii) options to purchase 367,500 Ordinary Shares, with a weighted average exercise price of $7.93 per share, had not vested as of July 31, 2020 (including options
        vested within 60 days of this date). Of the 367,500 unvested options on July 31, 2020, options to purchase 35,000 Ordinary Shares, 130,000 Ordinary Shares, 105,000 Ordinary Shares, 60,000 Ordinary Shares and 37,500 Ordinary Shares are expected to
        vest during 2020, 2021, 2022, 2023 and 2024, respectively. These options were granted under the 2010 Plan.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">19</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">It is proposed that the following resolutions be adopted at the Meeting:</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb40a155e4df24479a4cff5a2802d425e">

            <tr>
              <td style="width: 35.45pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>&#8220;<font style="font-weight: bold;">RESOLVED </font>that the<font style="font-weight: bold;">&#160;</font>gross monthly base salary of Dr. Cohen-Dayag in her position as the Company&#8217;s Chief Executive Officer be increased to NIS 134,125,
                  effective as of March 1, 2020&#8221;; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze178fa5dd1164ad18c98ca2749c5241a">

            <tr>
              <td style="width: 35.45pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>&#8220;<font style="font-weight: bold;">RESOLVED</font> that the payment of a special cash bonus to Dr. Anat Cohen-Dayag in her capacity as the Company&#8217;s Chief Executive Officer, in the amount of NIS 395,840 be, and hereby is, approved&#8221;; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaace5bf2c1bd4300b047e087b144993f">

            <tr>
              <td style="width: 35.45pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">(iii)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>&#8220;<font style="font-weight: bold;">RESOLVED</font>, that the annual cash bonus plan for the years 2021, 2022 and 2023 to Dr. Anat Cohen-Dayag in her capacity as the Company&#8217;s Chief Executive Officer, as described in this Item 3, be, and
                  hereby is, approved&#8221;; and</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z281dcf798e0c4eeaa3fab8f647119d95">

            <tr>
              <td style="width: 35.45pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">(iv)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>&#8220;<font style="font-weight: bold;">RESOLVED</font>, that the annual equity award plan for the years 2021, 2022 and 2023 and the employee share purchase plan for the year 2020, 2021, 2022 and 2023 to Dr. Anat Cohen-Dayag in her capacity
                  as the Company&#8217;s Chief Executive Officer, as described in this Item 3, be, and hereby are, approved.&#8221;</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 0.3pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the Ordinary Shares represented and voting on this proposal at the Meeting in person, by proxy or through the Electronic
        Voting System is required for the approval of each of our Chief Executive Officer&#8217;s compensation items - the salary increase, special cash bonus, annual cash bonus plan and equity arrangements; provided that, the majority of the shares voted in
        favor of this proposal are not held by &#8220;controlling shareholders&#8221; or shareholders with &#8220;personal interest&#8221; in the approval of such proposal, not taking into account any abstention, or that the total number of shares referred to above voted against
        this proposal, does not exceed two (2) percent of the aggregate voting rights in the Company.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 0.3pt; line-height: 1.25;">Please see Item 2 above for the definitions of the terms &#8220;controlling shareholders&#8221; and &#8220;personal interest&#8221;.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 0.3pt; line-height: 1.25;"><font style="font-weight: bold;">Please note that we consider it highly unlikely that any of our shareholders is a controlling shareholder or has a personal interest in this
          proposal</font>. However, as required under Israeli law, the enclosed form of proxy requires that you specifically indicate whether you are, or are not, a controlling shareholder or have a personal interest in this proposal. Without indicating to
        this effect, we will not be able to count your vote with respect to this proposal.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">The Board recommends that the shareholders vote &#8220;FOR&#8221; the proposed resolutions.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">ITEM NO. 4</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">APPROVAL OF AN ANNUAL EQUITY AWARD PLAN TO THE NON-EXECUTIVE MEMBERS </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">OF THE BOARD OF DIRECTORS OF THE COMPANY</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Background</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, arrangements regarding the compensation of a director of a publicly traded company, require approvals of the compensation committee, board of directors and company&#8217;s
          shareholders, in that order.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">As specified in Item 1, our non-executive directors, except for Mr. Paul Sekhri, our non-executive chairman of the Board, are entitled to an annual grant of 10,000 options in each year of service
        following the initial year of service (for which they are entitled to the Initial Option Grant), in addition to their annual cash fees. However, Mr. Paul Sekhri, our non-executive chairman of the Board, is currently not entitled to an annual grant
        of equity, similar to the annual option grant to which other non-executive directors are entitled, but only to an annual cash fee as specified in Item 1.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">20</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Below is a table of the options held by our non-executive directors as of July 30, 2020 (including the 2020 annual option grant):</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="za4c95681d5bb4c9397aa71408d7d9924">

          <tr>
            <td style="width: 20.82%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Name of Non-Executive Director</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Total Number of Options<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Weighted Average Exercise Price per Option</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Number of Vested Options as of July 31, 2020</div>
            </td>
            <td style="width: 20.66%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Number of Unvested Options as of July 31, 2020</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20.82%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Mr. Paul Sekhri</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">500,000</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">$2.85</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">312,500</div>
            </td>
            <td style="width: 20.66%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">187,500</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20.82%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Mr. Eran Perry</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">45,000</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">$6.19</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">-</div>
            </td>
            <td style="width: 20.66%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">45,000</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20.82%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Mr. Gilead Halevy</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">55,000</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">$5.66</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">15,308</div>
            </td>
            <td style="width: 20.66%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">39,692</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20.82%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Dr. Jean-Pierre Bizzari</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">55,000</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">$5.69</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">15,308</div>
            </td>
            <td style="width: 20.66%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">39,692</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20.82%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Dr. Kinneret Livnat Savitzky</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">55,000</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">$5.66</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">15,308</div>
            </td>
            <td style="width: 20.66%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">39,692</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20.82%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">Mr. Sandy Zweifach</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">60,000</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">$5.01</div>
            </td>
            <td style="width: 19.51%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">22,500</div>
            </td>
            <td style="width: 20.66%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9pt;">37,500</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf8edb15d348a445c935b70d2a6ca3263">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;(1)</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', serif; font-size: 9pt;">As of July 30, 2020, none of the options granted to our non-executive directors, including our non-executive chairman of the Board, were exercised since their day of
                issuance.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Equity Award Plan</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">As remuneration for his contribution and efforts as a non-executive chairman of the Board and in line with the limitations set forth in our Compensation Policy with respect to equity-based
          compensation for non-executive chairman of the board, the Compensation Committee and the Board approved in their separate meetings held on July 28, 2020 and July 29, 2020, respectively, an annual equity award plan (the &#8220;<font style="font-weight: bold;">Equity Award Plan</font>&#8221;) to Mr. Sekhri, in his role as the non-executive chairman of the Board, according to which Mr. Sekhri will be granted 10,000 options to purchase Ordinary Shares each year, starting from 2020 and for each of the
          following years of service (each such grant, a &#8220;<font style="font-weight: bold;">Chairman&#8217;s Annual Option Grant</font>&#8221;), under the terms detailed below.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">The grant date of each Chairman&#8217;s Annual Option Grant will be such date in each year on which the Board approves the annual equity grants to other Office Holders (provided that the service of Mr.
          Sekhri as director continues at the time of each grant), with an exercise price equal to the closing price of the Company&#8217;s ordinary shares on the Nasdaq on the last trading day prior to such Board approval, and the grant date of the Chairman&#8217;s
          Annual Option Grant for the year 2020 will be the day of the Meeting with an exercise price equal to the closing price of the Company&#8217;s ordinary shares on the Nasdaq on the last trading day prior to such date. The Chairman&#8217;s Annual Option Grants
          will be subject (other than as described herein) to the terms and conditions of the 2010 Plan, or to the terms of any other equity-based incentive plan the Company may adopt in the future and pursuant to which such Chairman&#8217;s Annual Option Grants
          would be granted. Each Chairman&#8217;s Annual Option Grant shall vest over a four-year period as follows: 25% of the options granted shall vest on the first day of the quarter one calendar year immediately following the quarter in which the options
          were granted and an additional 6.25% of the options granted shall vest each quarter thereafter for the next thirty six (36) months. Notwithstanding the terms of the relevant equity-based incentive plan, all options granted to Mr. Sekhri pursuant
          to the Equity Award Plan shall become fully vested immediately upon the completion of one or more of the following events, whether by way of a consolidation, merger or reorganization of the Company or otherwise: (a) a sale of all or substantially
          all of Company&#8217;s issued share capital or assets to any other company, entity, person or a group of persons, or (b) the acquisition of more than 50% of the Company&#8217;s equity or voting power by any shareholder or group of shareholders. Further,
          notwithstanding the terms of the relevant option plan, all options granted which shall be vested as of the date of final termination of office as a non-executive director of the Company may be exercised within one (1) year following such
          termination of office.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">Furthermore, the Compensation Committee and the Board determined that instead of an Annual Option Grant and Chairman&#8217;s Annual Option Grant, the Compensation Committee and the Board may issue to
          all non-executive directors, including Mr. Sekhri, Other Equity,&#160;in which case the Annual Option Grant and Chairman&#8217;s Annual Option Grant of 10,000 options shall be&#160;adjusted to 5,000 units of Other Equity awards, provided, that with respect to an
          annual equity grant that combines both types of equity awards (<font style="font-style: italic;">i.e.</font>, options and Other Equity), such grant shall be adjusted, on a&#160;pro rata&#160;basis, to give effect to the relative portion of each type of
          equity awarded (for illustration purposes, if the Compensation Committee and Board approve the grant of 4,000 RSUs to the non-executive directors and non-executive chairman of the Board, the relevant&#160; annual equity grant will be comprised of a
          total of 6,000 units, out of which 4,000 will be RSUs and 2,000 will be options).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">21</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; line-height: 1.25;">The provisions relating to vesting, acceleration and exercise period applicable to the options, as specified above, shall apply to Other Equity that may be granted as set forth above, <font style="font-style: italic;">mutatis mutandis</font>.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Our Compensation Committee and Board believe that the proposed Equity Award Plan to Mr. Paul Sekhri and the proposed change that allows issuance of Other Equity to all current non-executive
        directors (including our non-executive chairman of the Board) and future non-executive directors, is in the Company&#8217;s best interests and is in line with the compensation philosophy, objectives, limits and caps set forth in the Compensation Policy.
        When reaching their conclusion, our Compensation Committee and Board analyzed all factors and considerations required under the Compensation Policy and the Companies Law, including comparable industry data and data of the Peer Group that showed
        that the proposed Equity Award Plan is within the average of the Peer Group, the responsibilities and duties of Mr. Sekhri in his position as the Company&#8217;s non-executive chairman of the Board, and his expected contribution to the Company. In
        addition, the Compensation Committee and Board determined that the proposed Equity Award Plan and the potential issuance of Other Equity suitably links pay to performance, aligns our non-executive directors&#8217; interests with those of the Company and
        its shareholders over the long term and encourages balanced risk management.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">It is proposed that the following resolution be adopted at the Meeting:</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font> that the annual grant of options to purchase 10,000 Ordinary Shares to Mr. Paul Sekhri, the Company&#8217;s Chairman of the
          Board, for the year 2020 and onwards, pursuant to the Equity Award Plan and pursuant to the terms described in this Item 4, be, and hereby are, approved, and that the Company may issue to all of its current and future non-executive directors
          (including its non-executive Chairman) Other Equity pursuant to the terms specified in this Item 4.&#8221;</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="margin-right: 0.3pt; line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The affirmative vote of holders of the majority of the Ordinary Shares represented and voting at the Meeting in person, by proxy or through the Electronic Voting System, is required for the
        approval of the above resolution.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;">The Board recommends that the shareholders vote &#8220;FOR&#8221; the proposed resolution.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">ITEM NO. 5</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">RE-APPOINTMENT OF INDEPENDENT AUDITOR</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">Background</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The Companies Law and our Articles provide that an independent auditor of the Company shall be appointed at the annual general meeting of shareholders of the Company.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">General</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Company&#8217;s current independent registered public accounting firm, Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global (&#8220;<font style="font-weight: bold;">KFGK</font>&#8221;), is
        hereby being nominated for re-appointment as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2020, and until the next annual general meeting of shareholders.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">KFGK has served as the Company independent auditor since 2002 and has no relationship with the Company or with any affiliate of the Company except as auditor, tax consultant and as a provider of
        other consultancy services.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">As a result of the combined provisions of the Israeli law, the Articles and the Sarbanes-Oxley Act of 2002, the appointment of the independent registered public accounting firm requires the
        approval of the shareholders of the Company, and its remuneration requires the approval of the Board, following approval and recommendation by the Audit Committee. The Audit Committee and the Board have reviewed, and are satisfied with, the
        performance of KFGK, and have approved and are recommending to shareholders to approve their re-appointment as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December 31, 2020, and until the next annual
        general meeting.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The Audit Committee&#8217;s policy is to pre-approve all audit and non-audit services provided by the Company&#8217;s independent registered public accounting firm, KFGK.&#160;These services may include audit
        services, tax services and other consulting services.&#160;Additional services may be pre-approved by the Audit Committee on an individual basis.&#160;Once services have been pre-approved, the Company&#8217;s independent registered public accounting firm and
        management then report to the Audit Committee on a periodic basis regarding the extent of services actually provided in accordance with the applicable pre-approval, and regarding the fees for the services performed.&#160;Such fees for 2019 and 2018 were
        pre-approved by the Audit Committee in accordance with these procedures.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">22</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">The following table presents the aggregate amounts of fees paid or to be paid by the Company to KFGK for the services rendered in the fiscal years ended December 31, 2019 and 2018:</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="center" id="z8024680d46f84ed8b9de8897b7e0bcb2" style="width: 70%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

          <tr>
            <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">2019</div>
                <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">2018</div>
                <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
              </div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Audit Fees</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">133,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">146,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; line-height: 1.25;">Audit Related Fees</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25;">32,500</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25;">90,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Tax Fees</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">8,077</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">6,500</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(255, 255, 255);">
              <div style="text-align: justify; line-height: 1.25;">All Other Fees</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25;">2,500</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255);">
              <div style="line-height: 1.25;">2,500</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 2.85pt; line-height: 1.25; font-weight: bold;">Total</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">176,077</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-weight: bold;">245,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Audit Fees&#8221; are fees for professional services rendered by our principal accountant in connection with the integrated audit (including review of internal control over financial reporting) of our
        consolidated annual financial statements and review of our unaudited interim financial statements;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Audit Related Fees&#8221; are fees for professional services rendered by our principal accountant in connection with the audit and other assignments, including consultancy and consents with respect to
        an underwritten public offering and related prospectus supplements filed with the SEC;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Tax Fees&#8221; are fees for services rendered by our principal accountant in connection with tax compliance, tax advice and tax planning which in years 2019 and 2018 were consultancy relating to
        withholding tax on payments to foreign suppliers, annual Israeli tax reports and VAT related services; and</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;All Other Fees&#8221; are fees for other consulting services rendered by our principal accountant to us.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;<font style="font-weight: bold;">It is proposed that the following resolution be adopted at the Meeting:</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 0.3pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font>, that Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global, be, and hereby is, re-appointed as the Company&#8217;s
        independent registered public accounting firm for the fiscal year ending December 31, 2020, and until the next annual general meeting of shareholders, <font style="background-color: #FFFFFF;">and to authorize the Board, upon recommendation of the
          Audit Committee, to determine the remuneration of </font>Kost Forer Gabbay &amp; Kasierer, a member of Ernst &amp; Young Global, <font style="background-color: #FFFFFF;">in accordance with the volume and nature of its services</font>.&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-right: 0.3pt; line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The affirmative vote of a majority of the Ordinary Shares represented and voting on this proposal at the Meeting in person, by proxy or through the Electronic Voting System, is required for the
        approval of the above resolution.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">The Board recommends that the shareholders vote &#8220;FOR&#8221; the proposed resolution.</div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="background-color: #FFFFFF; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-variant: small-caps; font-weight: bold;">RECEIPT AND CONSIDERATION OF THE COMPANY&#8217;S CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR 2019</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">At the Meeting, you will also have an opportunity to discuss the consolidated financial statements of the Company for the fiscal year ended December 31, 2019.&#160; <font style="font-weight: bold;">This






          item will not involve a vote of the shareholders.</font></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Our 2019 consolidated financial statements, as well as our Annual Report on Form 20-F for the year ended December 31, 2019 (filed with the SEC on February 24, 2020), may be viewed on our website at
        http://cgen.com/investors/reports, through the EDGAR website of the SEC at www.sec.gov, through the Israeli Securities Authority&#8217;s electronic filing system at http://www.magna.isa.gov.il, or through the website of the Tel-Aviv Stock Exchange Ltd.
        at http://maya.tase.co.il. None of the audited consolidated financial statements, 2019 Form 20-F or the contents of our website forms part of the proxy solicitation material.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" id="za803218a221b42c68150df9ae20a9102" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50%;">
                <div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By Order of the Board of Directors,</div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>/s/ Paul Sekhri</u></div>
                  <div style="line-height: 1.25;">&#160;</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Paul Sekhri</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Chairman of the Board</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Holon, Israel</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">August 5, 2020</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">23</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
      <div style="text-align: center; text-indent: -241pt; margin-left: 241pt; line-height: 1.25; font-weight: bold;"><u>Exhibit A</u></div>
      <div style="text-align: center; text-indent: -241pt; margin-left: 241pt; line-height: 1.25; font-weight: bold;"><u>Compugen Ltd.</u></div>
      <div style="text-align: center; text-indent: -241pt; margin-left: 241pt; line-height: 1.25; font-weight: bold;"><u>Amended and Restated Compensation Policy</u></div>
      <!--PROfilePageNumberReset%Num%2%A - %%-->
      <div style="line-height: 1.25">&#160;
        <div id="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" id="zbf1fa0de6dad423d9348744b8da7ca80" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100%; vertical-align: top;">
                  <div style="text-align: right; line-height: 1.25;"><img width="136" height="52" src="image00004.jpg"></div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
        </div>
        <div style="text-align: center; margin-right: 212.35pt; margin-left: 231.7pt; line-height: 1.25; font-weight: bold;">Compugen Ltd.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; margin-right: 146.65pt; margin-left: 165.75pt; line-height: 1.25; font-weight: bold;">Compensation Policy for Directors and Officers</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; margin-right: 124.15pt; margin-left: 143.15pt; line-height: 1.25; font-weight: bold;">(Revised and Restated &#160;<strike>October 19</strike><u> September 16</u>, 20<strike>17</strike><u>20</u>)</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="margin-left: 5.9pt; line-height: 1.25;"><font style="font-weight: bold;">1.</font> &#160; &#160; <font style="font-weight: bold;">General</font></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.55pt; margin-left: 23.8pt; line-height: 1.25;">This Compensation Policy outlines the philosophies and principles pursuant to which Compugen Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;)





          will compensate its directors, chief executive officer (&#8220;<font style="font-weight: bold;">CEO</font>&#8221;) and other &#8220;office holders&#8221;, as such term is defined in the Israeli Companies Law, 5759-1999 (&#8220;<font style="font-weight: bold;">Office Holders</font>&#8221;
          and the &#8220;<font style="font-weight: bold;">Companies Law</font>&#8221;, respectively).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.55pt; margin-left: 23.8pt; line-height: 1.25;">This Compensation Policy is intended to meet the requirements of applicable law and will be periodically reviewed by the Compensation Committee of the
          Company&#8217;s Board of Directors, or any other committee of the Board assuming the responsibilities of the Compensation Committee (the &#8220;<font style="font-weight: bold;">Compensation Committee</font>&#8221;<u> or the &#8220; </u><font style="font-weight: bold;"><u>Committee</u></font><u>&#8221;
          </u>&#160;and the &#8220;<font style="font-weight: bold;">Board</font>&#8221;, respectively) and the Board in order to ensure that the provisions hereof and their implementation meet legal requirements and the Company&#8217;s business needs.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 23.8pt; line-height: 1.25;">Nothing in this Compensation Policy shall obligate the Company to grant any particular type or amount of compensation to any Office Holder, unless
          expressly stated otherwise, nor shall it derogate from approval procedures mandated by the Companies Law.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.8pt; margin-left: 23.8pt; line-height: 1.25;">The term &#8220;officer&#8221;, as used in this Compensation Policy, includes all Office Holders other than directors. However, to the extent the chairman of the
          Board is an active chairman (an &#8220;<font style="font-weight: bold;">Active Chairman</font>&#8221;), or to the extent there are other directors who also hold management positions (each an &#8220;<font style="font-weight: bold;">Executive Director</font>&#8221;), the
          term &#8220;officer&#8221; shall also refer to such Active Chairman or other Executive Directors.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 50.35pt; margin-left: 23.8pt; line-height: 1.25;">Any amendment to this Compensation Policy shall require the approvals as set forth in the Companies Law.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="margin-left: 5.9pt; line-height: 1.25;"><font style="font-weight: bold;">2.</font>&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Philosophy and Objectives</font></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 23.8pt; line-height: 1.25;">The Company&#8217;s Compensation Policy is structured to attract and retain the highest caliber talent, reward strong performance and align incentives with the
          creation of long-term shareholder value, taking into account the Company&#8217;s size and nature of its activities, and ensuring that the Company&#8217;s Office Holders are not incentivized to take excessive risks that may be detrimental to shareholder value
          in the long-term.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.6pt; margin-left: 23.8pt; line-height: 1.25;">Taking into account the Company&#8217;s nature as a world-wide innovative therapeutic discovery and development company, in early stages of drug development,
          the Compensation Policy is also designed to achieve the following:</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 3.25pt; margin-left: 23.8pt; line-height: 1.25;">&#8226;&#160;&#160; Motivate our Office Holders to pursue the Company&#8217;s strategic opportunities while effectively managing the risks and challenges inherent to a<strike>n
            early-stage</strike>&#160;biotechnology company.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">
          <div style="text-align: justify; margin-right: 3.25pt; margin-left: 23.8pt; line-height: 1.25;">&#8226;&#160;&#160; Improve business results and strategy implementation, and support the Company&#8217;s work-plans, from a long-term perspective.</div>
          <div style="text-align: justify; margin-right: 3.25pt; margin-left: 23.8pt; line-height: 1.25;"> <br>
          </div>
        </div>
        <div style="text-align: justify; margin-right: 142.65pt; margin-left: 23.8pt; line-height: 1.25;">&#8226;&#160;&#160; Incentivize Office Holders to create long-term economic value for the Company.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 7.55pt; margin-left: 23.8pt; line-height: 1.25;">&#8226;&#160;&#160; Create a clear line-of-sight between officers&#8217; compensation and both Company-wide and individual performance.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.8pt; margin-left: 23.8pt; line-height: 1.25;">The Company draws upon a pool of talent that is highly sought after by large and established global pharmaceutical and biotechnology companies as well as
          by other life science companies and high tech, which operate both within and outside the Company&#8217;s geographic areas. Compugen believes it must offer a compensation package to all of its Officer Holders, as well as its other employees, that is
          competitive with the companies from whom it may recruit.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.85pt; margin-left: 23.8pt; line-height: 1.25;">Additionally, the Company values integrity, honesty, ethical conduct and fairness, and views them as an essential part of its compensation philosophy.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="margin-left: 5.9pt; line-height: 1.25;"><font style="font-weight: bold;">3.</font>&#160;&#160; &#160; <font style="font-weight: bold;">Officers&#8217; Compensation Package Components</font></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 128.699pt; margin-left: 23.8pt; line-height: 1.25;">Officers&#8217; compensation packages will generally be comprised of the following elements:</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 420.1pt; margin-left: 23.8pt; line-height: 1.25; font-weight: bold;">a.&#160;&#160; Base Salary</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 410.5pt; margin-left: 23.8pt; line-height: 1.25; font-weight: bold;">b.&#160;&#160; Cash Bonuses</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="margin-right: 350.45pt; margin-left: 23.8pt; line-height: 1.25;"><font style="font-weight: bold;">c.</font>&#160;&#160;&#160; <font style="font-weight: bold;">Equity-based Compensation </font></div>
        <div style="margin-right: 350.45pt; margin-left: 23.8pt; line-height: 1.25;"><font style="font-weight: bold;"> <br>
          </font></div>
        <div style="margin-right: 350.45pt; margin-left: 23.8pt; line-height: 1.25;"><font style="font-weight: bold;">d. &#160;&#160; Benefits and Perquisites</font></div>
        <div id="DSPFPageHeader">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
        </div>
        <div style="text-align: justify; margin-right: 372.9pt; margin-left: 23.8pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">e.&#160;&#160;&#160; Termination Payments</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <!--PROfilePageNumberReset%Num%2%A - %%-->
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 5.8pt; line-height: 1.25;">The &#8220;mix&#8221; of the elements that will be provided to each officer will be structured in order to compensate officers for Company-wide and individual
          performance and align their interests with shareholder interests, while recognizing that the mix may vary from period to period and from officer to officer and the fact that given its nature as a world-wide innovative therapeutic discovery and
          development company, in early stages of drug development, the Company may, from time to time, see fit to incentivize its officers to pursue innovative thinking, persistent drive to success and riskier strategies, which may create long-term
          economic value for the Company.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.65pt; margin-left: 5.8pt; line-height: 1.25;">Accordingly, the actual compensation mix during any given period may deviate substantially from any previous or subsequent period and significantly, cash
          bonuses and/or equity-based compensation may not be granted at all during certain periods.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 305.45pt; margin-left: 5.8pt; line-height: 1.25; font-weight: bold;">3.1.&#160; &#160; Determining Officers&#8217; Compensation</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.75pt; margin-left: 5.8pt; line-height: 1.25;">When determining officers&#8217; compensation, the following will be considered, in addition to the principles, philosophies and objectives mentioned above:</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 184.05pt; margin-left: 5.8pt; line-height: 1.25;">&#8226;&#160;&#160; The officer&#8217;s position, scope of responsibility and business challenges.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 171.95pt; margin-left: 5.8pt; line-height: 1.25;">&#8226;&#160;&#160; The officer&#8217;s skills, professional experience, education and qualifications.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 239.05pt; margin-left: 5.8pt; line-height: 1.25;">&#8226;&#160;&#160; The officer&#8217;s performance results and accomplishments.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 202.55pt; margin-left: 5.8pt; line-height: 1.25;">&#8226;&#160;&#160; The officer&#8217;s previous compensation arrangements and seniority.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25">
          <div style="margin: 0px 0px 0px 5.8pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">&#8226;&#160;&#160; </font>Paying officers equitably relative to one another based on their position, responsibilities, location, education,
            experience, qualifications, performance results and accomplishments.</div>
          <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
          </div>
          <div style="margin: 0px 0px 0px 18pt; line-height: 1.25; text-indent: -12pt;">&#8226;&#160;&#160; The relationship between the officer&#8217;s compensation package and the compensation of the Company&#8217;s other employees (including those employed by manpower contractors)
            and specifically the median and average compensation and the effect of such relationship on work relations in the Company.</div>
          <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; margin-right: 202.55pt; margin-left: 5.8pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> </div>
          </div>
          <div style="text-align: justify; margin-right: 202.55pt; margin-left: 5.8pt; line-height: 1.25;">
            <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
            </div>
          </div>
        </div>
        <div style="text-align: justify; margin-right: 2.6pt; margin-left: 5.8pt; line-height: 1.25;">In addition, the Company may, from time to time, review its compensation practices in comparison with those of companies in similar businesses and fields
          (<font style="font-style: italic;">e.g.</font>, high-tech and biotech), of similar size (<font style="font-style: italic;">e.g.</font>, in terms of market value, shareholder equity and number of employees) and stage of development, as well as
          with those of companies in relevant locations and/or which compete with the Company for similar talent.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 409.65pt; margin-left: 5.8pt; line-height: 1.25; font-weight: bold;">3.2.&#160; &#160; Base Salary</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.95pt; margin-left: 5.8pt; line-height: 1.25;">Base salaries are a fixed compensation element which provides compensation to an officer for performance of his or her duties and responsibilities. Base
          salaries will be initially negotiated and generally set forth in officers&#8217; employment or service agreements, taking into consideration the matters set forth in Section 3.1 above (Determining Officers&#8217; Compensation), as applicable.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 5.8pt; line-height: 1.25;">Possible adjustments to officers&#8217; base salaries may be periodically reviewed, considered and approved based on considerations applied for initially
          determining an officer&#8217;s base salary.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 5.8pt; line-height: 1.25;">Officers may be granted a one-time cash or equity award (or a mix thereof) upon recruitment or promotion which shall not exceed, in terms of value, 100%
          of an officer&#8217;s annual salary cost. The term &#8220;annual salary cost&#8221;, as used in this Compensation Policy, includes (i) an officer&#8217;s annual base salary; (ii) the Company&#8217;s contributions to pension/retirement savings (including on account of
          severance), study fund, social security and health insurance; (iii) car or travel related expenses; (iv) cellular phone; (v) recreation/convalescence pay and (vi) any other benefits that are mandated by applicable law or that are generally
          acceptable in the applicable employment market.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 400.05pt; margin-left: 5.8pt; line-height: 1.25; font-weight: bold;">3.3.&#160; &#160; Cash Bonuses</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 261.7pt; margin-left: 5.8pt; line-height: 1.25;">Officers may be granted annual and/or special cash bonuses (&#8220;<font style="font-weight: bold;">Annual Cash Bonuses</font>&#8221; and &#8220;<font style="font-weight: bold;">Special Cash Bonuses</font>&#8221;, respectively), subject to the provisions set forth below.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 364.85pt; margin-left: 5.8pt; line-height: 1.25; font-weight: bold;">3.3.1.&#160; Annual Cash Bonuses</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.75pt; margin-left: 5.8pt; line-height: 1.25;">Annual Cash Bonuses are designed to promote the Company&#8217;s business results, strategy and work-plan, from a long- term perspective, by rewarding its
          officers for achieving the Company&#8217;s goals and for their individual performance.</div>
        <div id="DSPFPageHeader">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" id="DSPFPageNumber">A - 2</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
        </div>
        <div style="text-align: justify; margin-right: 2.95pt; margin-left: 5.8pt; line-height: 1.25;">The parameters for payment of the Annual Cash Bonus, as well as any relevant criteria may be determined in employment or service agreements, and may also
          be determined with respect to one year or more.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.6pt; margin-left: 5.8pt; line-height: 1.25;">To the extent not otherwise determined, subsequently or concurrently with the approval of the budget with respect to any calendar year, the Company shall
          determine, to the extent required to do so by the Companies Law, following recommendation of the CEO (and, with respect to the CEO, following the recommendation of the chairman of the Board and with respect to the Active Chairman and any other
          Executive Director, if any, following recommendation of the Compensation Committee), each officer&#8217;s annual cash target bonus, granted for the achievement of 100% of his target objectives ("<font style="font-weight: bold;">Annual </font><strike><font style="font-weight: bold;">t</font></strike><font style="font-weight: bold;"><u>T</u></font><font style="font-weight: bold;">arget Cash Bonus</font>") and maximum Annual Cash Bonus, as well as each officer&#8217;s objectives and related weights,
          including applicable thresholds, caps and the formula for calculating the Annual Cash Bonus with respect to such year, including multipliers, accelerators and decelerators to correlate each officer's payments with his actual achievements. <font style="font-style: italic;">&#160;</font><font style="font-style: italic;"><u>Objectives</u></font>: between &#160;<strike>40</strike><u>30</u>% and 60% of the Annual Cash Bonus will be based on Company-wide <strike>performance </strike><u>measurable
            criteria. The measurable criteria and&#160; their relative weight shall be determined by the</u><u>&#160;Compensation Committee and the Board in respect to each calendar year, provided that at least two measurable criteria&#160;will be set by the Compensation
            Committee and the Board for any calendar year. These measurable criteria may include,&#160;<font style="font-style: italic;">inter alia</font>, significant objectives relating to the progress of clinical trials, progress of pipeline products,
            operational,&#160;financial and business targets, and any additional significant objectives determined by the Compensation Committee&#160;</u><u>and the Board derived from the Company&#8217;s annual work plan and strategy</u><strike>(</strike><font style="font-style: italic;"><strike>e.g.</strike></font><strike>, commercialization agreements, product&#160;development milestones and operating results)</strike>&#160;(&#8220;<font style="font-weight: bold;">Company Objectives</font>&#8221;) and between <strike>25</strike><u>20</u>%
          and <strike>45</strike><u>55</u>% of the Annual Cash Bonus will be based on performance &#160;<strike>specific to the </strike>&#160;relevant <u> to the </u>officer&#8217;s &#160;<u>specific </u>&#160;area of responsibility (<font style="font-style: italic;">e.g.</font>,
          product <u> research and</u>&#160;discovery,<u> product</u>&#160;<strike> unit efficiency and </strike>development of discovery capabilities<u>, unit efficiency, etc.</u>) (&#8220;<font style="font-weight: bold;">Individual Objectives</font>&#8221;). Both Company
          Objectives and Individual Objectives may combine quantitative and qualitative goals, provided that, to the extent required by the Companies Law, there is a clear and measurable index for each goal.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.65pt; margin-left: 5.8pt; line-height: 1.25;">With respect to the CEO, the Active Chairman and any other Executive Director, if any, between 80% and 100% of the Annual Cash Bonus will be based on
          Company Objectives, due to such persons&#8217; direct line-of sight and impact on Company-wide performance<u>, provided, that notwithstanding the foregoing and in compliance with the Companies Law,</u><u>&#160;the Compensation Committee and the Board of
            Directors may determine with respect to the CEO that up to three (3)&#160;</u><u>monthly base salaries will be based on non-measurable criteria as determined thereby</u>.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 3.65pt; margin-left: 5.8pt; line-height: 1.25;">The Company may modify the objectives and their related weights and any thresholds during the calendar year in response to special or unaccounted for
          events.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.65pt; margin-left: 5.8pt; line-height: 1.25;"><font style="font-style: italic;"><u>Discretionary Component</u></font>: A non- substantial portion of up to 20% of the &#160;<u>Annual Cash Bonus </u><strike>objectives





          </strike>for each year may be based on non-measurable criteria. If and to the extent permissible pursuant to the Companies Law, our Compensation Committee and our Board of Directors &#160;<strike>(and with respect to our CEO and any Executive Director
            with the&#160;approval of our shareholders as well) </strike>may increase the portion of &#160;<strike>targets </strike>&#160;<u>the Annual Cash Bonus </u>that &#160;<strike>are </strike>&#160;<u>is </u>&#160;based on non-measurable criteria above the rate of 20%, up
          to the maximum portion permissible pursuant to the Law, but not to more than 50%<u> and with respect to the CEO for up to three (3) monthly base salaries</u>. Such non-measurable criteria may be determined by our CEO with the approval of our
          Compensation Committee and our Board of Directors .</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 89.95pt; margin-left: 5.8pt; line-height: 1.25;"><font style="font-style: italic;"><u>Cap</u></font>: <u>T</u><strike>t</strike>he Annual Target Cash Bonus of each officer shall not exceed six (6)
          monthly base salaries, or with respect to the CEO, the Active Chairman and any other Executive Director, if any, nine (9) monthly base salaries.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.65pt; margin-left: 5.8pt; line-height: 1.25;">The maximum Annual Cash Bonus for each Office Holder in a given year shall be capped as determined by our Board of Directors, but in no event shall
          exceed 150% of such Office Holder's Annual Target Cash Bonus. The Company may determine that with respect to any specific year, all or any particular officer or officers shall not be entitled to an Annual Cash Bonus. The Committee and the Board
          may also reduce or cancel any payment under the Annual Cash Bonuses in circumstances which the Committee and the Board deem it to be appropriate.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.75pt; margin-left: 5.8pt; line-height: 1.25;">Adjustment to the targets of the Company Objectives and/or the Individual Objectives may be made, when applicable, following acquisitions, mergers,
          execution of a material collaboration or advanced partnered program or a significant change in the Company's business environment.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 387.15pt; margin-left: 5.8pt; line-height: 1.25; font-weight: bold;">3.3.2.&#160; Special Bonuses</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.9pt; margin-left: 5.8pt; line-height: 1.25;">In addition to the Annual Cash Bonus, our Compensation Committee and Board may, to the extent they deem it is required, grant an officer a Special Bonus
          in cash or equity (or a mix thereof) either under special circumstances, or for special contributions, achievements, assignments or a change of control. Such bonuses are intended to enable the Company to adapt to unexpected or unaccounted for
          events or occurrences and to strengthen the Company&#8217;s ability to compete in a dynamic business environment. The conditions for receipt of such Special Bonus and the method of calculation thereof will be determined by the Committee and the Board
          in advance.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" id="DSPFPageNumber">A - 3</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; margin-right: 2.75pt; margin-left: 5.8pt; line-height: 1.25;">The Committee and the Board may also, in their sole discretion, grant a Special Bonus for significant or extraordinary achievements or efforts that
          produced an exceptional result.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 3.35pt; margin-left: 5.8pt; line-height: 1.25;"><font style="font-style: italic;"><u>Cap</u></font>: The maximum value of the total Special Bonuses paid to an officer with respect to any calendar year,
          will not exceed 6 (six) monthly base salaries.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 340.35pt; margin-left: 5.8pt; line-height: 1.25; font-weight: bold;">3.4.&#160; &#160; Equity-based Compensation</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.75pt; margin-left: 5.8pt; line-height: 1.25;">Equity-based compensation is generally designed to align officers&#8217; interests with the long-term interests of shareholders and to incentivize officers to
          create long-term economic value for the Company.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 5.8pt; line-height: 1.25;">Considering its nature as a world-wide innovative biotechnology company, &#160;<strike>in early stages of </strike>&#160;<u>focused on </u>&#160;research and
          development, it is the Company&#8217;s view that its officers should be incentivized to pursue innovative thinking, as well as realize key strategic opportunities, which will create long-term economic value for the Company<strike>, and therefore, stock</strike>&#160;<strike>options





            are currently the key equity-based compensation vehicle</strike>.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.5pt; margin-left: 5.8pt; line-height: 1.25;"><strike>In the future, the</strike><u>The</u>&#160;Company may offer various other types of equity-based compensation vehicles (<font style="font-style: italic;">e.g.</font>, <u>options,</u>&#160;performance shares, restricted shares, restricted share units, performance share units, phantom shares, <u>employee&#160;share purchase plan,</u>&#160;etc.), as well as a mix between such vehicles. When determining
          the types of equity-based vehicles and the mix between them, if any, the Company will consider among other things, the types of equity-based awards then available to the Company and the balance between aligning officers&#8217; and shareholders&#8217;
          interests and the Company&#8217;s risk management policy at the time.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 5.8pt; line-height: 1.25;">Equity-based awards will generally be granted on an annual basis. In certain circumstances, awards may be made on an ad hoc basis.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.65pt; margin-left: 5.8pt; line-height: 1.25;">The passage of time will generally be a sufficient criteria for the vesting of equity-based awards, but additional criteria may be determined, whether
          generally or with respect to specific grants, specific individuals or otherwise. &#160;<u>Options shall&#160;be issued with an exercise price not below the closing price of the Company&#8217;s ordinary shares on the Nasdaq on the last </u><u>trading day prior
            to the date of issuance thereof (and with respect to issuance of options which is subject to shareholder&#160;approval, as approved by the shareholders) (&#8220; </u><font style="font-weight: bold;"><u>FMV</u></font><u>&#8221; and &#8220; </u><font style="font-weight: bold;"><u>FMV Options</u></font><u>&#8221; ).</u></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 3.2pt; margin-left: 5.8pt; line-height: 1.25;"><u>Company shall not effect, without shareholder approval, any repricing of awards to Office Holders (except as applicable&#160;in connection with an equitable
            adjustment or a change of control).</u></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.8pt; margin-left: 5.8pt; line-height: 1.25;"><u>In addition, at least 30% of the value of any annual equity award to officers, will be granted in FMV Options or in other&#160;form(s) of equity which
            vesting is based on both time and performance criteria, as may be determined by the&#160;Compensation Committee and Board. This restriction shall not apply if the total value of the annual award is lower than&#160;US$100,000.</u></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.65pt; margin-left: 5.8pt; line-height: 1.25;">Equity-based awards will be granted pursuant to the Company&#8217;s 2010 Share Incentive Plan and/or any other equity- based incentive plan that the Company
          may adopt in the future, subject to the availability thereunder, and generally on the terms provided for therein and as determined by the Company, provided that any equity-based award to officers, <u>except for awards under employee share
            purchase plan,</u>&#160;must vest not less than a minimum period of three (3) years from the date of grant and shall include a maximum exercise period of ten years from the date of grant.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.8pt; margin-left: 5.8pt; line-height: 1.25;">Until otherwise determined, and to the extent legally available and applicable, equity-based awards to officers who are subject to Israeli taxation will
          be granted through a trustee pursuant to the provisions of Section 102 of the Israeli Income Tax Ordinance [New Version], 5721-1961 (the &#8220;<font style="font-weight: bold;">Income Tax Ordinance</font>&#8221;), under the capital gains route.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 5.8pt; line-height: 1.25;">The Company shall have the discretion to provide, generally or for specific officers, for the accelerated vesting of equity- based awards upon a change of
          control of the Company or upon termination of service or employment of the officer, and may extend the exercise period of equity-based awards beyond those generally applicable pursuant to the relevant plan, provided such extension does not extend
          beyond ten years from the date of grant.<u> With respect to the terms of</u><u> officers who may join the Company in the future, only &#8220;double trigger&#8221; vesting acceleration mechanisms shall be </u><u>permitted.</u></div>
        <br>
        <div style="text-align: justify; margin-right: 2.9pt; margin-left: 5.8pt; line-height: 1.25;"><strike>In addition, in no event shall the aggregate value of annual and ad hoc equity-based awards granted to an officer during&#160;any calendar year,
            calculated as of the date of their grant, exceed 300% of such officer&#8217;s annual base salary.</strike></div>
        <div id="DSPFPageHeader">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" id="DSPFPageNumber">A - 4</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
        </div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 5.8pt; line-height: 1.25;"><u>Any one or more equity awards granted to an officer in a single calendar year (referred to collectively as an &#8220; </u><font style="font-weight: bold;"><u>Annual</u></font><u><font style="font-weight: bold;">&#160;</font></u><font style="font-weight: bold;"><u>Grant</u></font><u>&#8221;), shall be subject to the vesting periods set forth above and to the following thresholds: (i) with respect to an&#160;Annual Grant of awards with an
            exercise price equal at least to the FMV, the portion of such Annual Grant that is&#160;scheduled to vest in any year following the grant date, shall not exceed 0.06% of the issued and outstanding share capital of the Company on the date of grant
            (the &#8220;</u><font style="font-weight: bold;"><u>Annual Threshold</u></font><u>&#8221;); (ii) with respect to an Annual Grant of RSUs or </u><u>other equity awards, the Annual Threshold shall be reduced by 50% (i.e., 0.03% of the issued and outstanding
            share&#160;capital of the Company on the date of grant); and (iii) with respect to an Annual Grant that combines both types of&#160;equity awards (i.e., equity awards with an exercise price equal to FMV and RSUs or other equity awards), the
            Annual&#160;Threshold shall be calculated, on a pro rata basis, to give effect to the relative portion of each type of equity awards.</u></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.8pt; margin-left: 5.8pt; line-height: 1.25;"><u>The Annual Threshold under this Section 3.4, shall be subject to an additional maximum cap, which is based on a market&#160;capitalization of US$ 3 billion
            (i.e. if Company&#8217;s market capitalization exceeds US$ 3 billion, the permitted dilution&#160;threshold for any equity awards shall be adjusted downwards to the number of awards reflecting the maximum Annual&#160;Threshold at a market capitalization of
            US$3 billion).</u></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 60.2pt; margin-left: 5.8pt; line-height: 1.25;">The Company may from time to time consider determining a cap for the exercise value of equity awards.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 354.2pt; margin-left: 5.8pt; line-height: 1.25; font-weight: bold;">3.5.&#160; &#160;&#160; Benefits and Perquisites</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.65pt; margin-left: 5.8pt; line-height: 1.25;">Benefits and perquisites are designed to supplement cash and equity compensation and provide officers with additional terms generally acceptable in the
          workforce, in order to enable the Company to attract and retain qualified people in a competitive market. In addition, certain benefits and perquisites (<font style="font-style: italic;">e.g.</font>, pension, vacation and sick pay) are mandated
          by applicable law.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.55pt; margin-left: 5.8pt; line-height: 1.25;">The cost to the Company of all benefits and perquisites (other than the cost of termination related benefits which are dealt with separately below and
          the cost of benefits associated with relocation) to any particular officer that are not mandated by law shall not exceed with respect to any particular calendar year, 30% of such officer&#8217;s annual salary cost.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.8pt; margin-left: 5.8pt; line-height: 1.25;">In the event of relocation of an officer to another geography, the benefits provided will include customary benefits associated with such relocation (such
          as travel, housing and shipping allowances, healthcare and children&#8217;s education) and may exceed 30% of the officer&#8217;s annual salary cost.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.6pt; margin-left: 5.8pt; line-height: 1.25;">The CEO shall be entitled to determine that non-material changes (i.e. not exceeding an amount equal to two monthly base salaries for any calendar year)
          may be made to the terms of the benefits and perquisites, but not to the base salary or variable components, of all officers reporting, directly or indirectly, to the CEO, without seeking the approval of the Compensation Committee.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 362.45pt; margin-left: 5.8pt; line-height: 1.25; font-weight: bold;">3.6.&#160; &#160; Termination Payments</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.85pt; margin-left: 5.8pt; line-height: 1.25;">Termination payments are generally intended to comply with applicable laws and to provide compensation to officers in the event of termination, including
          voluntary termination in circumstances which would not entitle the Company to terminate service or employment for &#8220;cause&#8221;.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.8pt; margin-left: 5.8pt; line-height: 1.25;">Termination payments may be provided for in employment or service agreements. When determining termination payments, the Company will generally consider,
          <font style="font-style: italic;">inter alia</font>, the term of service or employment, Company performance during such term, the contribution of the officer to the achievement of the Company&#8217;s goals and maximization of its profits, the
          circumstances of termination and the officer&#8217;s compensation during the term of service or employment.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 21.8pt; margin-left: 5.8pt; line-height: 1.25;">Termination payments the Company may provide for include, but are not limited to, one or more of the following:</div>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z1844e04348934457a91af1944a2ded95" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 5.75pt;"><br>
              </td>
              <td style="width: 17.25pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><u>Notice period</u>: advance notice of termination period, not to exceed three (3) months, or with respect to the CEO, the Active Chairman and any other Executive Director, if any, six (6) months. During the notice period, officers
                  will be entitled to full compensation, including benefits, and will be required to continue work, at the discretion of the Company. The Company may waive an officer&#8217;s services during the advance notice period and pay the officer in lieu
                  thereof, including the value of benefits.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z40c9dd787e414de4b4081e0aa36f51c0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 5.75pt;"><br>
              </td>
              <td style="width: 17.25pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><u>Change of Control</u>: change of control events, such as mergers and acquisitions, may expose the Company and its officers to a great deal of uncertainty. By providing its officers with compensation in events of change of control,
                  the Company reduces to some extent the personal uncertainty of its officers, and thus promotes full and impartial consideration of change of control opportunities. In light of the above, the Company may provide, in addition to any
                  discretionary termination payments as set forth below, for the payment of up to six (6) monthly base salaries to officers in the event their service or employment is terminated during the first year following a pre-defined change of
                  control event, including in the event of voluntarily termination.</div>
              </td>
            </tr>

        </table>
        <div id="DSPFPageHeader">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" id="DSPFPageNumber">A - 5</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
        </div>
        <div style="line-height: 1.25"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="fd710dc8f0054ca9b19b5295b0480d6f" class="DSPFListTable">

            <tr>
              <td style="width: 23.75pt;"></td>
              <td style="width: 17.25pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;"><u>Severance payment</u>: the greater of the amount of severance pay payable pursuant to the Israeli Severance Pay Law, 5723-1963, had the officer been entitled to severance
                pay pursuant to such law, and the amount accumulated in an officer&#8217;s pension fund and/or managers insurance and/or provident fund.</td>
            </tr>

        </table>
        <div style="line-height: 1.25"> <br>
        </div>
        <table cellspacing="0" cellpadding="0" id="z2320af23d2f44a2c90836f0e45a84435" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 23.75pt;"><br>
              </td>
              <td style="width: 17.25pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><u>Discretionary (including adaptation) payments</u>: in special cases, up to three (3) monthly base salaries, or with respect to the CEO, the Active Chairman and any other Executive Director, if any, six (6) monthly base salaries.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z97ee541ebe5449eeb182f27038e85c45" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 23.75pt;"><br>
              </td>
              <td style="width: 17.25pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><u>Relationship After Termination</u>: the Company may engage an officer after the termination of his or her service or employment in a different capacity, such as a consultant, if the Company deems it appropriate due to such officer's
                  expertise, knowledge, experience and/or special contribution; provided that the terms of such engagement are approved according to the applicable terms of this Policy and any applicable law.</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="margin-left: 5.9pt; line-height: 1.25;"><font style="font-weight: bold;">4.</font>&#160; &#160;&#160; <font style="font-weight: bold;">Non-executive Directors</font></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.65pt; margin-left: 23.8pt; line-height: 1.25;">Directors who do not hold any employment or similar position with the Company and including external directors and other independent directors, if any,
          pursuant to the Companies Law, are referred to herein as &#8220;<font style="font-weight: bold;">Non-executive Directors</font>&#8221;.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="margin: 0px 0px 0px 23.8pt; line-height: 1.25; text-align: justify;">The Company aims to provide reasonable and fair compensation to its Non-executive Directors taking into account the Company&#8217;s business environment and its values of
          integrity, equality and fairness.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.9pt; margin-left: 23.8pt; line-height: 1.25;">The Company also believes that this Policy should be structured so as to allow the Company to attract and retain world- class experts who may be located
          either within or outside the Company&#8217;s geographic areas to serve as its directors and assist the Company in becoming a global cutting-edge bio-technology company developing first-in class therapeutics. In order to do so, Compugen believes it must
          be able to offer directors compensation packages competitive with those offered by companies with whom it competes for such directors. External directors, if any, shall be compensated in accordance with the Companies Regulations (Rules regarding
          Compensation and Expenses to an External Director), 5760-2000, as&#160; amended by&#160; the&#160;&#160; Companies Regulations (Reliefs for Companies whose Shares are&#160;&#160; Registered for Trading on an Exchange Outside of Israel), 5760-2000, as such regulations may be
          amended from time to time (the &#8220;<font style="font-weight: bold;">Compensation Regulations</font>&#8221;), and may include equity-based compensation.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="margin-right: 181.3pt; margin-left: 23.8pt; line-height: 1.25;">Non-executive Directors&#8217; compensation will be comprised of the following: </div>
        <div style="margin-right: 181.3pt; margin-left: 23.8pt; line-height: 1.25;"> <br>
        </div>
        <div style="margin-right: 181.3pt; margin-left: 23.8pt; line-height: 1.25;">A. <font style="font-weight: bold; font-style: italic;">Cash Component</font>:</div>
        <div style="margin-right: 181.3pt; margin-left: 23.8pt; line-height: 1.25;"> <br>
        </div>
        <div style="margin: 0px 0px 0px 46.35pt; line-height: 1.25; text-align: justify;"><font style="font-weight: bold;">(1) Annual Fee</font>: up to twice the maximum amount permitted from time to time with respect to the Company in accordance with the
          Compensation Regulations.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 46.35pt; line-height: 1.25;">In certain circumstances, when it is required in order to attract a foreign based &#160;<u>Non-executive Director </u><strike>director</strike>&#160;who is an
          industry expert with significant global experience, or can provide the Company a significant added value that is material to the Company, the annual fee shall be capped at three times the maximum amount permitted from time to time with respect to
          the Company in accordance with the Compensation Regulations.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="margin: 0px 0px 0px 46.35pt; line-height: 1.25; text-align: justify;"><font style="font-weight: bold;">(2) Per-meeting Fee</font>: up to twice the maximum amount permitted from time to time with respect to the Company in accordance with
          the Compensation Regulations</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="margin: 0px 0px 0px 46.35pt; line-height: 1.25; text-align: justify;"><font style="font-weight: bold;">(3) Committee Membership Fee</font>: The Company can decide that its <u>Non-executive Directors</u><strike>directors</strike>, or
          that a certain &#160;<u>Non-executive Director</u><strike>director</strike>, will be entitled to an annual committee membership fee in an amount of up to US$10,000 per each committee in which such director is a member.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="margin: 0px 0px 0px 23.8pt; line-height: 1.25; text-align: justify;">Any of the aforementioned fees that are paid in US dollars shall be evaluated against the NIS value of the Compensation Regulations according to a US dollar to NIS
          exchange rate of 3.6 NIS per each 1 US dollar.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="margin: 0px 0px 0px 36pt; line-height: 1.25; text-align: justify; text-indent: -12pt;">B. <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Fixed Annual Equity Grant</font>: annual equity-based grant, with
          respect to a fixed number of shares of the Company and/or with a fixed value at grant. Such annual equity-based grant is intended to align Non-executive Directors&#8217; interests with the long-term interests of the Company&#8217;s shareholders. Equity-based
          grants shall be pursuant to the Company&#8217;s 2010 Share Incentive Plan and/or any other equity-based incentive plan that the Company may adopt in the future, subject to availability thereunder and generally on the terms provided for therein. Until
          otherwise determined, and to the extent legally available and applicable, equity-based awards to Non-executive Directors who are subject to Israeli taxation will be granted through a trustee pursuant to the provisions of Section 102 of the<font style="font-family: 'Times New Roman',Times,serif;"> Income Tax Ordinance, under the capital gains route. In no event shall the aggregate value of fixed annual equity- based awards granted to a </font><font style="font-family: 'Times New Roman',Times,serif;"><strike>n</strike></font><font style="font-family: 'Times New Roman',Times,serif;"><u>N</u></font><font style="font-family: 'Times New Roman',Times,serif;">on-executive </font><font style="font-family: 'Times New Roman',Times,serif;"><strike>d</strike></font><font style="font-family: 'Times New Roman',Times,serif;"><u>D</u></font><font style="font-family: 'Times New Roman',Times,serif;">irector during any calendar year, calculated as of the date of
            their grant, exceed 300% of such </font><font style="font-family: 'Times New Roman',Times,serif;"><strike>n</strike></font><font style="font-family: 'Times New Roman',Times,serif;"><u>N</u></font><font style="font-family: 'Times New Roman',Times,serif;">on-executive </font><font style="font-family: 'Times New Roman',Times,serif;"><strike>d</strike></font><font style="font-family: 'Times New Roman',Times,serif;"><u>D</u></font><font style="font-family: 'Times New Roman',Times,serif;">irector&#8217;s aggregate annual, committee membership and per-meeting fees for the preceding twelve (12) months (the "</font><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Equity Cap</font><font style="font-family: 'Times New Roman',Times,serif;">"); provided however that </font><font style="font-family: 'Times New Roman',Times,serif;">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;"><strike>when it is required in
              order to</strike></font><strike><font style="font-family: 'Times New Roman',Times,serif;">&#160;</font></strike><font style="font-family: 'Times New Roman',Times,serif;"><strike>attract a foreign based director who is an industry expert with
              significant global experience, or who can provide the</strike></font><font style="font-family: 'Times New Roman',Times,serif;">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;"><strike>Company with a significant added value
              that is material to the Company, </strike></font><font style="font-family: 'Times New Roman',Times,serif;">the initial equity grant can be up to the higher of: (i) such director's Equity Cap; or (ii) 60,000 Options.</font></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" id="DSPFPageNumber">A - 6</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; margin-right: 279.05pt; margin-left: 23.8pt; line-height: 1.25; font-style: italic; font-weight: bold;"><u>Non-Executive Chairman of the Board of Directors</u></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 148.5pt; margin-left: 23.8pt; line-height: 1.25;"><font style="font-weight: bold;">Annual Fee: </font>may be up to 150% of the cap that applies to Non-executive Directors.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 3pt; margin-left: 23.8pt; line-height: 1.25;">The residence of the Non-executive Chairman of the Board of Directors shall be taken into consideration in determining the parameters of his or her total
          compensation package.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.6pt; margin-left: 23.8pt; line-height: 1.25;">Other than as specifically set forth herein all other terms of the Non-Executive Chairman of the Board of Directors shall be the same as those of that
          apply to other <strike>n</strike><u>N</u>on-executive <strike>d</strike><u>D</u>irectors.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 312.85pt; margin-left: 23.8pt; line-height: 1.25; font-style: italic; font-weight: bold;"><u>General Terms for Director Compensation</u></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="margin: 0px 0px 0px 23.8pt; line-height: 1.25; text-align: justify;">Applicable value added tax will be added to the above compensation in accordance with applicable law.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="margin: 0px 0px 0px 23.8pt; line-height: 1.25; text-align: justify;">All <strike>D</strike><u>d</u>irectors will also be entitled to reimbursement of expenses, including for business travel, in accordance with Company policies.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 23.8pt; line-height: 1.25;">To the extent applicable, the annual and per-meeting fees will be adjusted and payable in accordance with the Compensation Regulations. Pursuant to the
          Compensation Regulations, there are, currently, automatic adjustments in the annual and per-meeting fees based on changes in the Israeli Consumer Price Index. The Compensation Regulations also currently provide for payment of partial per-meeting
          fees in the event resolutions are adopted in writing or by participation through various methods of communication and also enable increased payments to directors to the extent they are &#8220;experts,&#8221; as defined in the Compensation Regulations.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.75pt; margin-left: 23.8pt; line-height: 1.25;">Non-executive Directors&#8217; compensation may be periodically reviewed and considered by the Company. When reviewing and considering Non-executive
          Directors&#8217; compensation, the Company will consider, <font style="font-style: italic;">inter alia</font>, Non-executive Directors&#8217; previous compensation and the relationship between the contemplated compensation and the compensation of Company
          employees (including those employed by manpower contractors) and specifically the median and average compensation and the effect of such relationship on work relations in the Company. In addition, the Company will consider the residence of such <strike>n</strike><u>N</u>on-executive



          <strike>d</strike><u>D</u>irector and the applicable local benchmark information that applies to such residence.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="margin-right: 301.55pt; margin-left: 4.15pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">5.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">D&amp;O





            Insurance, indemnification and release</font></div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.8pt; margin-left: 23.8pt; line-height: 1.25;">The Company will release all current and future Office Holders from liability for a breach of their duty of care to the Company and provide them with
          indemnification to the fullest extent permitted by law and the Company&#8217;s Articles of Association (the &#8220;<font style="font-weight: bold;">Articles</font>&#8221;).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.65pt; margin-left: 23.8pt; line-height: 1.25;">In addition, until otherwise determined, the Company will purchase and periodically renew, at the Company&#8217;s expense, insurance coverage in respect of
          the liability of its current and future Office Holders to the maximum extent permitted by law providing for the coverage of up to US$<strike>50 </strike>&#160;<u>100 </u>&#160;million <strike>and the </strike>&#160;<u>with an </u>annual premium <strike>shall</strike><u>reflecting





            market&#160;terms</u>&#160;<strike>be&#160;</strike><u>and not having a substantial effect on the Company&#8217;s profitability, assets or obligations </u><strike>up to US$900,000</strike>, and <u>such insurance may </u><strike>will </strike>include coverage
          with respect to any public offering of shares or other securities of the Company. In addition, such insurance coverage may include &#8220;run-off&#8221; provisions covering an Office Holder&#8217;s liability following termination of service or employment. Our
          Compensation Committee shall be authorized to increase the coverage purchased<strike>, and/or the premium paid for such policies</strike>&#160;if such increase exceeds the defined cap<strike>s</strike> set forth above by up to 20% (beyond such cap<strike>s</strike>)
          in any year, as compared to the previous year, or cumulatively for a number of years, without an additional shareholders' approval, if and to the extent permitted under the Law. The CEO and/or any other person designated by him or her, shall have
          the authority to obtain, renew and keep in force and affect such insurance.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" id="DSPFPageNumber">A - 7</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="margin: 0px 0px 0px 4.15pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">6.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Recoupment and
            reduction of Compensation</font></div>
        <br>
        <div style="margin: 0px 0px 0px 4.15pt; line-height: 1.25; font-weight: bold; text-align: justify;">6.1.&#160;&#160; Clawback</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 2.75pt; margin-left: 5.8pt; line-height: 1.25;">An Office Holder will be required to return any compensation paid to him or her, that was paid on the basis of data included in the Company&#8217;s financial
          statements, which turned out to be erroneous and was restated in the Company&#8217;s financial statements on or before May 31<font style="font-family: Calibri, sans-serif; font-size: 6.5pt;">st </font>of the third year following the year in which the
          original financial statements were published, to the extent the compensation paid exceeds the compensation that would otherwise have been paid had the restated data been available at the time compensation based on such data was originally
          calculated.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.9pt; margin-left: 5.8pt; line-height: 1.25;">Our Compensation Committee and Board shall be authorized, to the extent permitted by applicable law, not to seek recovery to the extent that (i) to do so
          would be unreasonable or impracticable; or (ii) there is low likelihood of success under governing law versus the cost and effort involved.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; margin-right: 423.95pt; margin-left: 5.8pt; line-height: 1.25; font-weight: bold;">6.2.&#160; &#160; General</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 3.2pt; margin-left: 5.8pt; line-height: 1.25;">The Company shall have the authority to stipulate that, as a condition to the grant of any variable compensation to an Office Holder, that such variable
          compensation may be reduced in circumstances where such Office Holder&#8217;s conduct would justify termination for &#8220;cause&#8221; or in other circumstances determined by the Company as warranting such reduction.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 5.8pt; line-height: 1.25;">The Compensation Committee and our Board shall be authorized to approve a deviation of up to 10% from any limits, caps or standards detailed in this
          Compensation Policy, and such deviation shall be deemed to be in alignment with this Compensation Policy.</div>
        <div style="text-align: justify; margin-right: 2.7pt; margin-left: 5.8pt; line-height: 1.25;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal; font-family: 'Times New Roman',Times,serif;" id="DSPFPageNumber">A - 8</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div>
          <div id="DSPFPageHeader">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">FORM OF PROXY CARD</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">ANNUAL GENERAL MEETING OF SHAREHOLDERS</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SEPTEMBER 16, 2020</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">The shareholder(s) hereby appoints Anat Cohen-Dayag, Ari Krashin and Eran Ben Dor, or any one of them, as proxies, each with the power to appoint her or his substitute, and hereby authorizes
            them to represent and to vote as designated on the reverse side of this Proxy, all of the Ordinary Shares of Compugen Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) that the shareholder(s) is/are entitled to vote at the Annual
            General Meeting of Shareholders to be held at 5:00 p.m. (Israel time), on September 16, 2020, at the offices of the Company, 26 Harokmim Street, Bldg. D, Holon, Israel and any adjournment or postponement thereof (the &#8220;<font style="font-weight: bold;">Meeting</font>&#8221;).</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-weight: bold;">THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE SHAREHOLDER(S).&#160; IF NO SUCH DIRECTIONS ARE MADE, THIS PROXY WILL BE VOTED &#8220;FOR&#8221; ALL PROPOSALS AND IN THE
            DISCRETION OF THE PROXIES WITH RESPECT TO ALL OTHER MATTERS WHICH MAY PROPERLY COME BEFORE THE MEETING AND ANY AND ALL ADJOURNMENTS THEREOF.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;(Continued and to be signed on the reverse side)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <!--PROfilePageNumberReset%Num%2%B - %%-->
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">ANNUAL GENERAL MEETING OF SHAREHOLDERS OF</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SEPTEMBER 16, 2020</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25;">Please complete, sign, date and mail your proxy card in the envelope provided as soon as possible</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25;">_________________________________________________________________________</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; ALL PROPOSALS.</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE &#9746;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">_________________________________________________________________________</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="3" border="0" id="z0d0ba5d73f844943838e6b501ce25c7c" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; text-indent: -18pt; margin-left: 25.1pt; line-height: 1.25;"><font style="font-family: 'Times New Roman', Times, serif;">1.</font>&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">To
                      re-elect each of the directors specified below to serve as members of the Board of Directors of the Company <font style="background-color: #FFFFFF;">to hold office until immediately following the Company&#8217;s 2021 annual general meeting
                        and until his or her respective successor has been elected, or until his or her office </font>is vacated earlier in accordance with the provisions of the Companies Law and the Articles</font></div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">FOR</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">AGAINST</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ABSTAIN</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Paul Sekhri</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Anat Cohen-Dayag, Ph.D.</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Eran Perry</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Gilead Halevy</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Jean-Pierre Bizzari, M.D.</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Kinneret Livnat Savitzky, Ph.D.</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 42.55pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Sanford (Sandy) Zweifach</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; text-indent: -18pt; margin-left: 25.1pt; line-height: 1.25;"><font style="font-family: 'Times New Roman', Times, serif;">2.</font>&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">To
                      approve the Amended and Restated Compensation Policy of the Company</font></div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">FOR</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">AGAINST</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ABSTAIN</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="margin-right: 0.2pt; margin-left: 8.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Are you a &#8220;controlling shareholder&#8221; or do you have a &#8220;personal interest&#8221; in Item 2?</div>
                  <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                  <div style="text-align: justify; margin-right: 0.2pt; margin-left: 8.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Under the Companies Law, in general, a person will be deemed to be a &#8220;controlling shareholder&#8221; if
                    that person has the power to direct the activities of the company, otherwise than by reason of being a director or other office holder of the company.</div>
                  <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                  <div style="text-align: justify; margin-right: 0.2pt; margin-left: 8.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Under the Companies Law, in general, a person is deemed to have a personal interest if he or she,
                    or any member of his or her immediate family, or the immediate family of a shareholder&#8217;s spouse, has a personal interest in the adoption of the proposal; or if a company, other than the Company, that is affiliated with such person, has
                    a personal interest in the adoption of the proposal.</div>
                  <div style="text-align: justify; margin-right: 0.2pt; margin-left: 8.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><font style="background-color: #FFFFFF;">For further information regarding the definition of
                      &#8220;personal interest&#8221;, please see the explanation under Item 2 of the Proxy </font>Statement<font style="background-color: #FFFFFF;">.</font></div>
                  <div style="text-align: justify; margin-right: 0.2pt; margin-left: 8.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Please note - <font style="font-weight: bold;">you do not have a personal interest in the
                      adoption of this proposal just because you own our shares.</font></div>
                  <div style="text-align: justify; margin-right: 0.2pt; margin-left: 8.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">IF YOU DO NOT MARK ONE OF THE BOXES YOU WILL BE DEEMED TO BE A CONTROLLING SHAREHOLDER AND/OR HAVE
                    A PERSONAL INTEREST IN THIS ITEM.</div>
                  <div style="text-align: justify; margin-right: 0.2pt; margin-left: 8.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">PLEASE NOTE THAT IT IS <font style="font-weight: bold;">HIGHLY UNLIKELY THAT YOU ARE A
                      CONTROLLING SHAREHOLDER</font><font style="font-weight: bold;">&#160;</font>AND IT IS <font style="font-weight: bold;">UNLIKELY THAT YOU HAVE A PERSONAL INTEREST IN THIS ITEM.</font></div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">YES</div>
                  <div style="text-align: center; line-height: 1.25;"><img width="20" height="20" src="image00005.jpg"></div>
                </td>
                <td style="width: 9.01%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NO</div>
                  <div style="text-align: center; line-height: 1.25;"><img width="20" height="20" src="image00005.jpg"></div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 9.01%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; text-indent: -18pt; margin-left: 25.1pt; line-height: 1.25;"><font style="font-family: 'Times New Roman', Times, serif;">3.</font>&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">To
                      approve the following compensation to the Company&#8217;s Chief Executive Officer:</font></div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 25.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">3.1 A gross monthly base salary of NIS 134,125 effective as of March 1, 2020</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">FOR</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">AGAINST</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ABSTAIN</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 25.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Are you a &#8220;controlling shareholder&#8221; or do you have a "personal interest" in Item 3.1?</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">YES</div>
                  <div style="text-align: center; line-height: 1.25;"><img width="20" height="20" src="image00005.jpg"></div>
                </td>
                <td style="width: 9.01%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NO</div>
                  <div style="text-align: center; line-height: 1.25;"><img width="20" height="20" src="image00005.jpg"></div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 25.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">3.2 A payment of a special cash bonus in the amount of NIS 395,840</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">FOR</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">AGAINST</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ABSTAIN</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 25.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Are you a &#8220;controlling shareholder&#8221; or do you have a "personal interest" in Item 3.2?</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">YES</div>
                  <div style="text-align: center; line-height: 1.25;"><img width="20" height="20" src="image00005.jpg"></div>
                </td>
                <td style="width: 9.01%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NO</div>
                  <div style="text-align: center; line-height: 1.25;"><img width="20" height="20" src="image00005.jpg"></div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 25.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">3.3 Annual cash bonus plan for the years 2021, 2022 and 2023</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">FOR</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">AGAINST</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ABSTAIN</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 25.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Are you a &#8220;controlling shareholder&#8221; or do you have a "personal interest" in Item 3.3?</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">YES</div>
                  <div style="text-align: center; line-height: 1.25;"><img width="20" height="20" src="image00005.jpg"></div>
                </td>
                <td style="width: 9.01%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NO</div>
                  <div style="text-align: center; line-height: 1.25;"><img width="20" height="20" src="image00005.jpg"></div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 25.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">3.4 Annual equity award plan for the years 2021, 2022 and 2023 and an employee share purchase plan for the years 2020,
                    2021, 2022 and 2023</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">FOR</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">AGAINST</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ABSTAIN</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-left: 25.1pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Are you a &#8220;controlling shareholder&#8221; or do you have a "personal interest" in Item 3.4?</div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">YES</div>
                  <div style="text-align: center; line-height: 1.25;"><img width="20" height="20" src="image00005.jpg"></div>
                </td>
                <td style="width: 9.01%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NO</div>
                  <div style="text-align: center; line-height: 1.25;"><img width="20" height="20" src="image00005.jpg"></div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; margin-right: 0.2pt; margin-left: 8.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Please refer to Item 2 above for the definitions of &#8220;controlling shareholder&#8221; and &#8220;personal
                    interest&#8221;.</div>
                  <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                  <div style="text-align: justify; margin-right: 0.2pt; margin-left: 8.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">IF YOU DO NOT MARK ONE OF THE BOXES IN ANY OF ITEMS 3.1 - 3.4 YOU WILL BE DEEMED TO BE A
                    CONTROLLING SHAREHOLDER AND/OR HAVE A PERSONAL INTEREST IN SUCH ITEM.</div>
                  <div style="text-align: justify; margin-right: 0.2pt; margin-left: 8.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">PLEASE NOTE&#160;THAT IT IS <font style="font-weight: bold;">HIGHLY UNLIKELY THAT YOU ARE A
                      CONTROLLING SHAREHOLDER</font><font style="font-weight: bold;">&#160;</font>AND IT IS <font style="font-weight: bold;">UNLIKELY THAT YOU HAVE A PERSONAL INTEREST IN ANY OF ITEMS 3.1 - 3.4.</font></div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 9.01%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 9.01%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; text-indent: -18pt; margin-left: 25.1pt; line-height: 1.25;"><font style="font-family: 'Times New Roman', Times, serif;">4.</font>&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">To approve
                      an annual equity award plan to the non-executive members of the Board of Directors</font></div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">FOR</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">AGAINST</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ABSTAIN</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.83%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 70.61%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify; text-indent: -18pt; margin-left: 25.1pt; line-height: 1.25;"><font style="font-family: 'Times New Roman', Times, serif;">5.</font>&#160;&#160;&#160; <font style="font-family: 'Times New Roman', Times, serif;">To
                      re-appoint Kost Forer Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global), as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2020, and until the next annual general
                      meeting and to authorize the Board, upon recommendation of the Audit Committee, to determine the remuneration of Kost Forer Gabbay &amp; Kasierer (a member of Ernst &amp; Young Global), in accordance with the volume and nature of its
                      services.</font></div>
                </td>
                <td style="width: 3.39%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 8.16%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">FOR</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 9.01%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">AGAINST</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
                <td style="width: 8.83%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">ABSTAIN</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" id="DSPFPageNumber">B - 2</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; line-height: 1.25;">To change the address on your account, please check the box at right and indicate your new address in the address space above. &#9744;</div>
          <div style="text-align: justify; margin-right: 1.3pt; line-height: 1.25;">Please note that changes to the registered name(s) on the account may not be submitted via this method.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">Signature of Shareholder&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>&#160; Date&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
            </u></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">Signature of Shareholder <u>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><u>&#160;</u>&#160; Date&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
            </u></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE:&#160; </font>Please sign exactly as your name or names appear on this Proxy.&#160; When shares are held jointly, each holder should sign. When signing as executor, administrator,
            attorney, trustee or guardian, please give full title as such.&#160; If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name
            by authorized person.</div>
        </div>
        <div> <br>
        </div>
      </div>
    </div>
  </div>
  <div style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" id="DSPFPageNumber">B - 3</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !G 4 # 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7G_ (WTR[O=;\R'0M;OHQ$JB:RUK[)'WXV>8O/OBO0*Y_Q?X=L==LMUUIMO
MJ%U;JQMXYI6B4L>Q9>0#CT-73ERRN!P']@7_ /T*?BG_ ,*C_P"W4?V!?_\
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M+6C?^ 4?^%=%15*<ELP.=_X0;PI_T+6C?^ 4?^%'_"#>%/\ H6M&_P# */\
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MJ33NF!GZ'HNFZ#8BRT:RALK4,7\J%=J[CU-:%%%2VWJP"BBBD 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" +=!"T# 2(  A$! Q$!_\0
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M?\)GX7_Z&31?_ ^+_P"*K\\L#T%&!Z"C^S(_S!]:?8_0W_A,_"__ $,FB_\
M@?%_\51_PF?A?_H9-%_\#XO_ (JOSRP/048'H*/[,C_,'UI]C]#?^$S\+_\
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M?\)GX7_Z&31?_ ^+_P"*K\\L#T%&!Z"C^S(_S!]:?8_0W_A,_"__ $,FB_\
M@?%_\51_PF?A?_H9-%_\#XO_ (JOSRP/048'H*/[,C_,'UI]C]#?^$S\+_\
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M?%_\57YY8'H*,#T%']F1_F#ZT^Q^AO\ PF?A?_H9-%_\#XO_ (JC_A,_"_\
MT,FB_P#@?%_\57YY8'H*,#T%']F1_F#ZT^Q^AO\ PF?A?_H9-%_\#XO_ (JC
M_A,_"_\ T,FB_P#@?%_\57YY8'H*,#T%']F1_F#ZT^Q^AO\ PF?A?_H9-%_\
M#XO_ (JC_A,_"_\ T,FB_P#@?%_\57YY8'H*,#T%']F1_F#ZT^Q^AO\ PF?A
M?_H9-%_\#XO_ (JC_A,_"_\ T,FB_P#@?%_\57YY8'H*,#T%']F1_F#ZT^Q^
MAO\ PF?A?_H9-%_\#XO_ (JC_A,_"_\ T,FB_P#@?%_\57YY8'H*,#T%']F1
M_F#ZT^Q^AO\ PF?A?_H9-%_\#XO_ (JC_A,_"_\ T,FB_P#@?%_\57YY8'H*
M,#T%']F1_F#ZT^Q^AO\ PF?A?_H9-%_\#XO_ (JC_A,_"_\ T,FB_P#@?%_\
M57YY8'H*,#T%']F1_F#ZT^Q^AO\ PF?A?_H9-%_\#XO_ (JC_A,_"_\ T,FB
M_P#@?%_\57YY8'H*,#T%']F1_F#ZT^Q^AO\ PF?A?_H9-%_\#XO_ (JC_A,_
M"_\ T,FB_P#@?%_\57YY8'H*,#T%']F1_F#ZT^Q^AO\ PF?A?_H9-%_\#XO_
M (JC_A,_"_\ T,FB_P#@?%_\57YY8'H*,#T%']F1_F#ZT^Q^AO\ PF?A?_H9
M-%_\#XO_ (JC_A,_"_\ T,FB_P#@?%_\57YY8'H*,#T%']F1_F#ZT^Q^AO\
MPF?A?_H9-%_\#XO_ (JC_A,_"_\ T,FB_P#@?%_\57YY8'H*,#T%']F1_F#Z
MT^Q^AO\ PF?A?_H9-%_\#XO_ (JC_A,_"_\ T,FB_P#@?%_\57YY8'H*,#T%
M']F1_F#ZT^Q^AO\ PF?A?_H9-%_\#XO_ (JC_A,_"_\ T,FB_P#@?%_\57YY
M8'H*,#T%']F1_F#ZT^Q^AO\ PF?A?_H9-%_\#XO_ (JC_A,_"_\ T,FB_P#@
M?%_\57YY8'H*,#T%']F1_F#ZT^Q^AO\ PF?A?_H9-%_\#XO_ (JC_A,_"_\
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M48'H*/[,C_,'UI]C]#?^$S\+_P#0R:+_ .!\7_Q5'_"9^%_^ADT7_P #XO\
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MXA\-&RTH68>(?:!:#[1PJ/\ ZSKUX^G%1[2?M%&VEBN6/*W<\456;.U6;'7
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M )%+X<_]@E?Z5X_3P[;@F_/\PJ?$%%%%;&84444 %%%% !1110 5]F?LJ_\
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MO_'WP=<W>NZMXUT_4-+N=$N%AE4I<CS22%3 3J>Q^F?2O$Z=N8H$+-L'(7/
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M/ ?B.)?-M4BN]/DOO(>&11SA<\YS7E/Q%T#7- CT]/$.N6VHW$QD(@AO#<&
M#;RQZ#.?_':XR-VC;=&S(WJIP:;W)/4]36].DZ=DGHO(RE-2Z:A1116YF%%%
M% !1110![S^Q_P#\CUK7_8-_]JI7UG7R9^Q__P CUK7_ &#?_:J5]9UX6/\
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MQP/:DK:G#DCRF<I<SN%%%%62%%%% !1110 4444 %?9G[*O_ "26'_K]G_\
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M,85@,XY']*N=-Q=J:M[K)C-->]W.YOE^)(\7OJ-KXHT*"QBGQ%IXOXUA6$'
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M-\D*W1C F"R,JL"PZ@=1Q75Z;JOAGQ]\-=&\.>(-:30=:T0^7;7$L)>*:+&
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M=?\ HEJZ>N8^*/\ R33Q9_V";K_T2U<M/XT:RV9^?5%%%?3GDA1110 4444
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M^^3_ (T?\*C\ _\ 0K:=_P!\G_&C^TJ?9A]5EW/@VBOO+_A4?@'_ *%;3O\
MOD_XT?\ "H_ /_0K:=_WR?\ &C^TJ?9A]5EW/@VBOO+_ (5'X!_Z%;3O^^3_
M (T?\*C\ _\ 0K:=_P!\G_&C^TJ?9A]5EW/@VBOO+_A4?@'_ *%;3O\ OD_X
MT?\ "H_ /_0K:=_WR?\ &C^TJ?9A]5EW/@VBOO+_ (5'X!_Z%;3O^^3_ (T?
M\*C\ _\ 0K:=_P!\G_&C^TJ?9A]5EW/@VBOO+_A4?@'_ *%;3O\ OD_XT?\
M"H_ /_0K:=_WR?\ &C^TJ?9A]5EW/@VBOO+_ (5'X!_Z%;3O^^3_ (T?\*C\
M _\ 0K:=_P!\G_&C^TJ?9A]5EW/@VBOO+_A4?@'_ *%;3O\ OD_XT?\ "H_
M/_0K:=_WR?\ &C^TJ?9A]5EW/@VBOO+_ (5'X!_Z%;3O^^3_ (T?\*C\ _\
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M -"MIW_?)_QH_P"%1^ ?^A6T[_OD_P"->O\ VE3[,XOJLNY\&T5]Y?\ "H_
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MWE_PJ/P#_P!"MIW_ 'R?\:/^%1^ ?^A6T[_OD_XT?VE3[,/JLNY\&T5]Y?\
M"H_ /_0K:=_WR?\ &C_A4?@'_H5M._[Y/^-']I4^S#ZK+N?!M%?>7_"H_ /_
M $*VG?\ ?)_QH_X5'X!_Z%;3O^^3_C1_:5/LP^JR[GP;17WE_P *C\ _]"MI
MW_?)_P :/^%1^ ?^A6T[_OD_XT?VE3[,/JLNY\&T5]Y?\*C\ _\ 0K:=_P!\
MG_&C_A4?@'_H5M._[Y/^-']I4^S#ZK+N?!M%?>7_  J/P#_T*VG?]\G_ !H_
MX5'X!_Z%;3O^^3_C1_:5/LP^JR[GP;17WE_PJ/P#_P!"MIW_ 'R?\:/^%1^
M?^A6T[_OD_XT?VE3[,/JLNY\&T5]Y?\ "H_ /_0K:=_WR?\ &C_A4?@'_H5M
M._[Y/^-']I4^S#ZK+N?!M?9G[*O_ "26'_K]G_\ 0A73?\*C\ _]"MIW_?)_
MQKI_#V@Z7X<TT6&AV45E9ARXBB&%W'J:Y\5C(UH<J1K1H.G*[9IT445YQTGE
MG[37_)&]8_ZZVW_H]*^)J_1S7M%T[Q!I<NG:S:17EC*5+PRC*L5((_(@&N5_
MX5'X!_Z%;3O^^3_C7H87%QHPY9(YJU%U'=,^#:*^\O\ A4?@'_H5M._[Y/\
MC1_PJ/P#_P!"MIW_ 'R?\:Z?[2I]F9?59=SX-HK[R_X5'X!_Z%;3O^^3_C1_
MPJ/P#_T*VG?]\G_&C^TJ?9A]5EW/@VBOO+_A4?@'_H5M._[Y/^-'_"H_ /\
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MO^%1^ ?^A6T[_OD_XT?\*C\ _P#0K:=_WR?\:/[2I]F'U67<^#:*^\O^%1^
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M][=+:Q8B,GEY!.[:._'?BO%!\,?C7XFC%_K'B>2SE?\ >);O>,-A]-J\+^%
M'UC17QKX?^)OCWX3>/8]#^(5U<7^G.Z^=]HD,Q$9X$L3GG YXZ'![U]DQL'1
M74Y5AD&@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5."#Y;5YAX_:[?X*^ 5M+V:UN9KK3HQ<(WSKN3!/N>:]C\5:0-?\,ZKI!F,
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MO7-:FC_#VSTGP/K&@6]Y/+<ZLD[7FHSJ&EFFE4AI& P.,\+QP/QH \Y\7_\
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M+'0%AADBTW5')E@\Q?FP<Y"GJ.:A_9\\":#%J7B'4TMIOMFF:Y<6]LQG<A4
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ML<#YJZ3P'/JT'P*\./H!L5O_ +%$!+?.5BB4GYG;'7 YQWJGX&\%:Y8?#'Q
M-=B63Q=KJS37:B13^\9=J)NSMX&!UQ5+7? GB"^^!GAS0(K6.34M.^SR7>F2
M7(1;M8SEX#(I*\^N<4 ,\*^.];L_B'I7A_5?$FA^)K;5%E7?81B*2TDC&3N
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MG[5;K&4\Z,2+S(H.5/!X)K$^)/BSQ#HB^"HO#<=K-=ZO<BW>*<81LQ9&3U4
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M $5IKDLA'DQO/Y2-SA@6/0CT-=+:-,]K"US&L<[(ID16R%;'(![X- $M%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?@FZN?L5OX/^'^M^%M8CEC8ZI<:F0D*J1NZ,?,R,\$<T ?26I #3+H   0L
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MAEU.X^U71,C-OD]>3Q]!0!NT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;)_>-,HH ?YLG]XT>;)_>-,HH ?YLG]XT>;)_>-,HH ?YLG]XT>;)_>-,HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF_/_ +-'S_[- #J*;\_^S1\_^S0 ZBF_/_LT?/\ [- #J*;\_P#LT?/_ +-
M#J*;\_\ LT?/_LT .HIOS_[-'S_[- #J*;\_^S1\_P#LT .HIOS_ .S1\_\
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M8:BD[A1116904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -3[S_7^@IU-3[S_ %_H*=0 4444 %%%% !1110 4444 %%%% !1110
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M *3(W8R,^F>:6O&_CE\/?%?B/5],U[P1K!LM1L86B,7G-$7!(/RL..W(/!H
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MANQ\N+$EU(,S3$<L?0>@KH*^CRG*5A5[6KK-_A_P36G3Y=6%%%%>V:A1110
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MW%P#[5V5%2ZEU:PU&S. _P"$*O!X\74_[9UHV8M-N\W:_?\ ,W>7C;G9C_\
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M/\"?:2[GHG_"UM3_ .@?9?FW^-'_  M;4_\ H'V7YM_C7G=%']KXS_GX_P
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M:>(_A-J/AKPA8W]A]GB1;2*_LIK3<Z,'',JKG<5Y;U.30!G^,(-6\#^%=/\
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MJ*H6.M:7?S>38ZE97,V-VR&=';'K@&I;;4;&ZN9;>VO+::XA_P!9%'*K,GU
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M:*YGX:^()_%/@71]9NXUBN;J'=*J= P)4X]B1FNFK.47%N+Z#"BBBD 4444
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MZ9/+,VP;RF<[=W7&><40VMO )1!!%&)7,DFQ -[$8)..IP!S[5R/_"RO#O\
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M/IUK>29+SP6J)(V>N6 R:NK9VRVTENMO"MO(7+Q! %?>26R.AR22?7)KDO\
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M^A'8U<KKC)22E%W3*"BBBJ **** &I]Y_K_04ZFI]Y_K_04Z@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME;R-OCDE!PIR3\QQ5GQ18V.B?'#P8^A0PVMW?0W,5[#;J$$L*ID%@..#R/\
MZU6J,;6ZM7)YV>A^'?%^@>)(KN30]4M[U+4XG,9/[OOSD>QJ'2_'/AG5;"_O
M=/UJTFM+ XN90Q"Q?4GZ5\N>#M6?P7X7N[R $'Q'IUS:QX.-UREPR*![[)/T
MK5TCP5?R>&_&^AZ-#]IFL-1LYGM2V#.%4,R^YZ\=ZWEA()N[T_JY"K-I:'TQ
MX9\4Z'XHM)+GP_J=M?PQMM=HF^Z?<'D5!HOC7PWKFK7&F:1K-G=W]OGS(8WR
MPP<'Z_A7@UQK%Y+XT\37FG>'+KPTLOA.<M:S((9"4/$I1>G)P#[5<T^RM=.L
M_@C=:5;0QWDYVRO& K2AH@6W$=>2>M9O#177^K7*]JSVFY\>>%K;Q NB3ZY8
MIJK,%%N9/FR>@STS^-=+7SWXY\-Z'=7DO@+P99&[UR_OEU#4-0?#FP7>&+-)
MC(] OO[BO>Y;.*?3VL[G=+$\?E/EB"PQ@\CFL:D(Q2:ZEQDVW<LT5Y3X;\.:
M/%-XFU<6TB0V-W)'9@W<K*AB7:2 6QRP)YJW8PR:L--T?4);K^S[;3!J%[#&
MS>9<22'*H2/F('S\#DD+0Z2Z,%-GI=%>6P7MBGAS7[;P_<:HD0G@M5L;R"6&
M2V>0KN"F3#8*MNQVY/>K7CSPWIUYKGAR P2M>7ETB32+<RH6AB7<PP& Y Q2
M]DKV;#FTT/2**YW5(K/POX1N8["UW0(/+2!I7.YI&"@;B2>2PK,'B:_AO/+@
MTV :7#?C3A(\S>9*<8)08P<,"#DCI4J#EJAN5MSM:*\Z\/Z[J=OJDDDMM%)I
MFI:K+%%(T[&7 7 *J 0$&QLY(/M38]1U34[_ $6;0+"#S'@N;Z1;BZ=81O<+
M&S$ L2RAR !@'Z57LF+G1Z/17GTOBY]1TNWNX[***\CLI[IO-G(6%TR@&0/F
M!8=:K^']>\21:1:V,5A976H6=DEYJ$L]TRJ/,W,J*=N2Y ;.0%&.M'LI6#G1
MZ317(Z!XIO/$.IH-+L(ETM8+>::XGE(=3+'O\L* <L R$Y(&&ZUUU1*+B[,I
M-/8****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 -3[S_7^@IU-3[S_7^@IU !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #
M?^6O_ :=3?\ EK_P&G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M7!_$+Q3J.@^*?!EA8>1]GU:_^SW/F)N.SC[ISP:J$7-V0F[*[.\HK@M:^+O@
MO1;R[M-1U8QW5K<&VFB$$C,K#J< ?=_VNGO6KXA\?>&O#^BVFJZGJD2V=V ;
M=HP9&F![JJ@D_E5>RGIH]1<\>YU%%<7=?$_PE:Z)INKSZH$T_4&=+>4Q/@L@
MRP(QE3QT..>*6^^)WA.Q\-V6N76I[+"])%O^Y?S),'!Q'C=QWXH]E/LPYX]S
MLZ*Y.Q^(GA>^\+7'B&WU2,Z7;G;-(R,K1MG 4H1N!.>!CFH_"GQ)\*^*1>_V
M1J:L;.,S3K/&T)2,=7PX'RCN>U+V<[-VV#FCW.PHKCO"?Q*\*^*]4ET[0]2\
M^[C4OM:)XPRCJ5+ !A]*J-\6_!2^(!HYUE#=^;Y.\1N8=_3'FXV=>.O6G[*=
M[<K#GCO<[RBJ&NZQI^@Z7-J.KW45K9PC+RR' 'M[GVKE?#_Q5\(>(/M@TS4R
M\EK"T\D<D$D;E%&255@"V/;-)0E)72T&Y).S9W-%>'_ _P ;7?C/QAKMQ=^(
MKF95>7[/I/V3;"EN&0)*'QPW."IYYS7N%.K3=.7*Q1DI*Z"BBBLR@HHHH **
M** "BL/6_$=OI%VMO-!-(S('RF,8)([GVK/_ .$XL_\ GUN?_'?\:Y9XZA3D
MXREJC-U8)V;.LHKD_P#A.+/_ )];G_QW_&C_ (3BS_Y];G_QW_&H_M'#?SB]
MM3[G645R?_"<6?\ SZW/_CO^-6])\4VVI7\5I%;SH\F<,V,# )]?:JCCL/*2
MC&6K&JT&[)G0T445UF@4444 %%%% !1110 4444 -EC26-HY55XW!5E89!![
M&O,+KX)>')V>!-1U^WT=Y/,;1X;\K9DYR?DQD<\\'Z5Z;+/#"0)I8XR>FY@,
MU']MM?\ GY@_[^"G&LZ>TK$RBI;G->)_A]H'B'2K"QGMY+/^S\?8I[)_)EML
M# V,.GZU#X/^'6D^&-2GU-;K4]5U::/R3?:I<F>8)_=!P !^%=7]MM?^?F#_
M +^"C[;:_P#/S!_W\%'MW;EYM Y8WN<$OP@\.C0]$TMYM0D@TB]:^MW:1-[.
MS;BK$+@KG'0 \=:O7?PST*]3Q*EXUY,FO3+<7 ,@'E.H^4QD $8Z\YKK_MMK
M_P _,'_?P4?;;7_GY@_[^"G]9E_,+DCV.7\(?#[2?#7VY_M&HZM=WL8@GN]4
MN//E>(=(\X V\GC']*S_  Q\*-!\.ZU%J5M=:K<FV#"RM[NZ\V&RW=?*4CC\
M2:[C[;:_\_,'_?P4?;;7_GY@_P"_@H^L/7WMQ\L3S"W^"6FVE]>7=AXJ\86<
MUY*9IS;:@L7F-G/.V,9Z]Z]4A3RH4CW,^Q0NYSDG'<GUJ+[;:_\ /S!_W\%'
MVVU_Y^8/^_@I3K\_Q2",5'8R(/"ME!X:N-%BEN1;SL[R2[AYA9FW,<XQU]J?
MJ_AR.^NH+NSOKW2KZ&/R1<693<T?78RR*Z$9 QE<CL1DUJ?;;7_GY@_[^"C[
M;:_\_,'_ '\%+VVM[CLC"L?!VGVD2 3WDTWVT7\\\T@9[B4)M!?C&,8X4+]T
M5IW.C6USKUGJTK2FXM(WCB7(V#?U.,9SCCK5K[;:_P#/S!_W\%'VVU_Y^8/^
M_@H=6^MPLB/5=.BU."*&X9Q''/'/M7'S,C!U!R#QD _A6<GABS2WM8?-N"MO
M=O>J2RY:5BQ)/'8L<5J_;;7_ )^8/^_@H^VVO_/S!_W\%)54E9,+(R8O"]G%
M;Z=%'-<A; 2^2=RY#2*RECQUP[8[<U2?P3;)/#-IVJ:IITD=G%8$VKQC=!'G
M:OS(<?>)W+AN>"*Z/[;:_P#/S!_W\%'VVU_Y^8/^_@JO;>8N5&!<>"=+DTZ>
MRB-Q;P260L5\IAF*,-N^4D$YSSSFF:AX+@O9&9M5U6%9[=+6\2%XT%XB@@;_
M ),J<%AF,H>?ICHOMMK_ ,_,'_?P4?;;7_GY@_[^"CV_]X.5%;1]'MM)-W]D
MW@7,HE8,1A<*J #CH H%:-5_MMK_ ,_,'_?P4?;;7_GY@_[^"I=1/5L>A8HJ
MO]MM?^?F#_OX*/MMK_S\P?\ ?P4N>/<98HJO]MM?^?F#_OX*/MMK_P _,'_?
MP4<\>X%BBJ_VVU_Y^8/^_@H^VVO_ #\P?]_!1SQ[@6**K_;;7_GY@_[^"C[;
M:_\ /S!_W\%'/'N!8HJO]MM?^?F#_OX*/MMK_P _,'_?P4<\>X%BBJ_VVU_Y
M^8/^_@H^VVO_ #\P?]_!1SQ[@6**K_;;7_GY@_[^"C[;:_\ /S!_W\%'/'N!
M8HJO]MM?^?F#_OX*/MMK_P _,'_?P4<\>X%BBD5@RAE(*GD$'(-+5 %%%% !
M1110 U/O/]?Z"G4U/O/]?Z"G4 %%%% !1110 5B^*/$EEX<M8IKT2NTS%(HH
M5W.Y )('('0=_:MHG YXKB-2@AUN[AN+LKY%Q<&UMP3CY CY8>Y;'_?(JX)7
MUV,ZC:C[NYKZ?XD;4;<3V6EWDL9X.'B!4^A!;(/L:S]0\?:?IMX+?4;6[@Q]
M^0!'6/V8JQY]NM8FGQ[K86L[R6VJ6EREG/)"^PRPG.,^HP.OM44UO;7O]I7J
M1QQ:98C[/;*>%+9Y;W/]:T48WU1@ZD[:/4]/1@ZAE((/((.0:6L?07-O)<:9
M(<FV.Z$G^*%L[?RY7\!5/Q-XQT_0-0M-/FBNKK4;L%H+:VB+LX'Z5DHN3LCI
M<U%<TCI**Y_PUXKLM>NKJSCBN;34;4 S6EU'LD4'HV.X]ZV[JXAM+=Y[F5(H
M4&6=VP%'N:'%Q=F$9*2NB6BD5@ZAE(*D9!'>C<N[;D;L9QGFI*%HHK&M/$5G
M=>)KS0HA-]MM85GD+)A=I.!@]Z:3>PG)+<V:*P-:\5Z?HNN:9I>H">.746V0
M2[/W9;^Z6['I^8K1US5;30])N=2U%_+M;=-\C8R<>U/DEIIN+GCKKL7J*SO#
M^K1:YI-OJ-M%/%#.NY%F3:Q'8XK1I--.S&FFKH****0PHHKDM4\=6-EJ-Y:0
M66HW[6(S=R6D!D2$XS@GU]JJ,7+8F4XQUDSK:*I:)J=OK.D6FHV1)M[F,2)N
M&#@^OO5VDTT[,:::N@HHKG]>\6:9HUC%=32-/'+=+9@VXWXD)Q@XZ8H47)V0
M2DHJ[.@HJ"]NH[.RFNI@QBB0R-M&3@#/ JGX:UFV\0Z':ZK8B06URI9!(,-@
M$CD?A19VN',KV-.BBBD,**** "BBB@!O_+7_ (#3J;_RU_X#3J "BBB@ HHH
MH **** "BFI(DBED=6 ."0<X(ID%S!<;OL\T4NTX;8X;'UQ0!+144%S!.S""
M:*0K]X(X;'UQ1%<P32-'#-%(Z?>57!(^HH EHHHH **** "O+_BQ8WEWXW^'
M<MK:7$\5OJF^9XHF=8EP.6('RCW->H45<)\DKBDN96/#M'T2Z^T?&"2;2Y_,
MNY95MW>V.9UV-@(2/F&?3/-8%AI^K>'['X7^)KO0-2U&TTRP>VNK2&W+W$#L
M3M;RS@Y'^<5](45LL2^W]6L9^R1XCXT%QXIO/A]?P^&;ZSM3K;32P36N65./
MWDJJ"$R?[WI47QTT'49/'&@Z\L7B)](@MFMY9/#\F+N%RQ(*CG@YYKW.BE'$
M.+32VO\ B-T[IW/G*UTC5=-^'/BW4_!EAXM2^O9X',NM%)+R95/SND87(8#H
M3DGMTJEX%TJ\E\?ZK?MI/C'4=.N/#T\6=?)6>X;<H,8?^#."%!.>_>OIJBJ^
MM.S5MR?9+34^>?AI#K3>(DTG1++Q''X:BL9HR/$-HB/92%2%6"7&XKVP.*XO
M1_",T>C#PSK^G?$B74A,5-G93(-,D;=D-O92JCODYKZZHIK%M-M(/8JVYY?\
M>- U+5? ]@NDVDFH-I][!=RVH.6FC3.1C^(^U8.CS7WCGXL>']>L_#NJ:-IF
MCVDD<\NH6_D/(S#A%&<D"O;J*SC6<8\MN_XEN%W<\P^ =C>6&C^)UO[6YMFD
MU^ZE03Q,A=#MPPR.0?6O3Z**SJ3YY.145RJP44DF[8VS&['&[IFO(X_$/B36
M?%UOI+W"V\)F.XVPPK(I.XANI!P14#/7:* , "B@ HHHH \[^(7_ "'(O^O=
M?_0FKF:Z;XA?\AR+_KW7_P!":N9KXW'_ .\3]3RZWQL****XS,*V_!?_ ",M
MI]'_ /0#6)6WX+_Y&6T^C_\ H!KHPG\>'JOS+I_&O4]/HHHK[8]4**** "BB
MB@ HHHH **** /)?C> ;[2<@']W)_-:\SVCT'Y5Z9\;O^/[2?^N<G\UKS2OS
M_.?]]J?+\D<E3XF)M'H/RHVCT'Y4M%>80)M'H/RHVCT'Y4M% ";1Z#\J-H]!
M^5+10 FT>@_*C:/0?E2T4 )M'H/RHVCT'Y4M% ";1Z#\J-H]!^5+10 FT>@_
M*C:/0?E2T4 )M'H/RHVCT'Y4M% ";1Z#\J-H]!^5+10 FT>@_*C:/0?E2T4
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M6&JZKH^WEZ?D;4Y_99ZO1117UIN%%%% #4^\_P!?Z"G4U/O/]?Z"G4 %%%%
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M55T'XB^$O$&L/I>CZ[:75^N?W*[@3CK@D '\*KV<M=-A<R[G2>=)_P ^TO\
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M:/\ A5VA_P#/?4/^_J__ !-']@8OR^\/92/%J*]I_P"%7:'_ ,]]0_[^K_\
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M .)H_L#%^7WA[*1XM17M/_"KM#_Y[ZA_W]7_ .)H_P"%7:'_ ,]]0_[^K_\
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M$CS*"RA$)CY/3!SCZ4[0M"O7^%^E^(9=2L[.WE\/C3KPWJLVV'<2KICJV#@
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M]&T6GJ=T-JPP9#V>3V]%_.@!(TDU]UEG5H])4[HXCP;CT9A_=]!WZ^E;P
M   X %%% !1110 4444 %%%% 'G?Q"_Y#D7_ %[K_P"A-7,UTWQ"_P"0Y%_U
M[K_Z$U<S7QN/_P!XGZGEUOC84445QF85M^"_^1EM/H__ * :Q*V_!?\ R,MI
M]'_] -=&$_CP]5^9=/XUZGI]%%%?;'JA1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -3[S_7^@IU
M-3[S_7^@IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #?^6O_ :=3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ;M8,2I'/J*,/_>7_OG_ .O3J* &X?\ O+_WS_\ 7HP_]Y?^^?\ Z].H
MH ;A_P"\O_?/_P!>C#_WE_[Y_P#KTZB@!N'_ +R_]\__ %Z,/_>7_OG_ .O3
MJ* &X?\ O+_WS_\ 7HP_]Y?^^?\ Z].HH ;A_P"\O_?/_P!>C#_WE_[Y_P#K
MTZB@!N'_ +R_]\__ %Z,/_>7_OG_ .O3J* &X?\ O+_WS_\ 7HP_]Y?^^?\
MZ].HH ;A_P"\O_?/_P!>C#_WE_[Y_P#KTZB@!N'_ +R_]\__ %Z,/_>7_OG_
M .O3J* &X?\ O+_WS_\ 7HP_]Y?^^?\ Z].HH ;A_P"\O_?/_P!>C#_WE_[Y
M_P#KTZB@!N'_ +R_]\__ %Z,/_>7_OG_ .O3J* &X?\ O+_WS_\ 7HP_]Y?^
M^?\ Z].HH ;A_P"\O_?/_P!>C#_WE_[Y_P#KTZB@!N'_ +R_]\__ %Z,/_>7
M_OG_ .O3J* &X?\ O+_WS_\ 7HP_]Y?^^?\ Z].HH ;A_P"\O_?/_P!>C#_W
ME_[Y_P#KTZB@!N'_ +R_]\__ %Z,/_>7_OG_ .O3J* &JIW9)!XQP,4ZBB@
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MPZ:I%N(8V5F.W:&?)(X'IWH ZBBBD90ZE6 (/4&@!:*@^QV__/%/RH^QV_\
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MBGY5)%#'%GRT5<]<"@!]%%% !1110!1UR*]GTB[BTJ2**^DC989)<[58C@G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 52U34$L(T^5I;B4[884^](?\/4]JNTWRT,@D*+Y@& V.<>F: ,W3-.D6
M8WNHLLM^XP,?=A7^ZO\ 4]ZU*** "BBB@ HHHH **** "BBB@ HHHH ****
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M !4]>=5E&4VX*R['I4HRC!1F[ON%%%%9F@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !3))8X@#*Z(#P"QQ3Z\K_:
M.A:5D _Z6>O^XU;8>E[:HJ=[7,ZL_9P<CTW[9;?\_$/_ 'V*/MEM_P _$/\
MWV*^0]B_W5_*C8O]U?RKU_[&7\_X?\$X?K[_ )?Q/KS[9;?\_$/_ 'V*/MEM
M_P _$/\ WV*^0]B_W5_*C8O]U?RH_L9?S_A_P0^OO^7\3Z]6ZMW8*L\3,>
MX)-35\N?#U5'CG0\*/\ CZ7M]:^HZ\[&X5862BG>YUX>M[9-VL%%%%<9N%%%
M% !1110 4444 %%%% 'G?Q"_Y#D7_7NO_H35S-=-\0O^0Y%_U[K_ .A-7,U\
M;C_]XGZGEUOC84445QF85M^"_P#D9;3Z/_Z :Q*V_!?_ ",MI]'_ /0#71A/
MX\/5?F73^->IZ?1117VQZH4444 %%%% !1110 4444 >1_$^>'2OBUX"U;5R
M(]'C\^!IG/[N.9U^0GL.>]=:_BSPO=^+K;2;2[M+K7IK9VAD@42&-!U!D7.W
M/7'M]*Z/5M,LM7L9++5+6&[M9!AXI5#*:S/#/@WP[X7:5O#^CV=@TG#M"F"?
MQK;GBXI.]T1RM/0\U^ WB#1M$\%:AINLWEMI^IV%Y<&]BNG".26)#<\MQ7GT
M<"WG@S2K@0LNDZEXX$UJC# >)MPW#V/]*^A=>\!^%M?OUO=9T*QO+M>DLD?S
M?CZUH7_A[2+^VL;>[T^WD@L9EGMHRN%BD7[K*!T(S6RQ$5)R2>I#IMJQ\G:N
MMUJ.@Z[H]ZA,7@K39[0,PZR-=!4(_P" *!^%>O?$:ZFU#PKX)\(6LIB.OM##
M<,OWE@506_ ]*]+N/"'A^X75A-I-JXU;;]NRO_'QMZ;OI5A_#VDR7NG7CV$#
M7.G(8[20CF%2,$+^%$L3&33MM_7YB5)I'FGQ!BM=#^*7PQED\JTT>U%U;*SX
M6.(^4 @)/3IQ]*K?"W1M-\4W7C\W\,5]HEQX@>:%#_JY"O\ %QPP_2O5_$&A
M:7XBTYK'7+&"^M&8,8IER,CH:ET;2K#1--AL-)M(;2SA&(XHEPJUG[;W++?_
M (-R^3WK]#S#]GJ-(8?%\4**D::Q*JHHP% Z "NA\3RZA+\0--_LG38-2DTZ
MPDE>.:Z\A4,SJJMG8V3B)QCCK75:-H>F:+]J_LJSBM?M4IGF\L8\QSU8^]6H
M[2".\FNTB5;B95220=65<[1^&X_G4SJIS<[ H-143S_6='U&/1=?UO48K>WO
MYS#*EM;OO6(1$8)? W-UYP*J^*KM]6\,>(-<BPT=Q;G2M)&2-WFL(R_3@LY
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M+9&5:#G!Q1\P45[Y_P *B\/?\]+W_O[_ /6H_P"%1>'O^>E[_P!_?_K5[O\
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MUUXA11_9.$_D_%_YA_:^,_G_  7^1[?_ ,+Y_P"I<_\ )[_[71_POGU\.?\
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M@ HHHH **** "BBB@ HHHH :GWG^O]!3J:GWG^O]!3J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HK)UW7;31XLSMNF;[D2_>/^ KBY=6U[Q%*8[%7
MCA[B+Y0/JU>=BLRI8>7LU>4^RW,IUHQ=MV>A7%[:VW_'Q<PQGT=P*K#7-+)Q
M]OML_P"^*X/4/#*:3I-SJFOZBEM:VZ>9,ZJ7*K7)P^*?A[-)'&OBEU9R%#/
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M[B9$BQ.2J 0AF\H[ 9,MD_-C ]:]BH **** "BBB@ HHHH **** /!OVE/\
MD):#_P!<9O\ T)*\:KZ ^.?A76_$=]I#Z+8/=I#'(LA5T7:25Q]XCT->8_\
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M2W4)5CO!\I$96&,8_=@@@G.3TQ6]116;=W=E)6"BBBD,**** "BBB@ HHHH
M**** "BBB@!J?>?Z_P!!3J:GWG^O]!3J "BBB@ HHHH **** "BBB@ HHHH
M**** "L?Q-K2:-8[\!KB3Y8D/<^I]A6NQ"J2> .37F<@?Q5XL*Y/V921Q_#&
MO7\S_.O-S+%3HP4*7QS=E_F95IN*M'=DWAW09]>N&U#5'<P,V<GK*?;T6O0K
M>WBMH5BMXUCC7@*HP*=#&D,21Q*%1!M51T I]:8' PPD--9/=]6.G34%YG%?
M&K_DE7B?_KS;^8KYJU;54N/AP+,^-M'N/]%C4:5'I^)V(Q^[\P#.[WK[$O%M
MWM91>+$UOM)D$H!7:.N<\8KP;PAXX-WX[M9K_0],M_"6JW$MMI-R+-$<21G
M);'\6/\ "O4IRLMB*L4WN>S^#2Q\)Z/OMWMF^R1 Q.<E/E'!JWJNEVFJ6QAO
M(@Z]FZ,ON#VJ[16)JX*4>62NCRJ\AO\ P=K$;HY>"0XCDZ+*/[K>C5Z3I.H0
MZG8QW-N?E8<CNI[@TS7-,@U?3)K.Y7*2#@]U;L1[UP'@'4)]+UZXTB^.'W^6
MV>[#[K?B/YBN7ZLL,_;4=(-^\NB;VDNR;T:Z.S/-A-X2NJ,G[LOA?GV_R_X&
MOIU%%%=1Z@4444 %%%% !1110 4444 %%%% !1110 W_ ):_\!IU-_Y:_P#
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M.MHK/T6_NK^!WO=)O-+=6VB.YDA=F'J/*=QCZG-6[:1YH5>6"2!SUC<J2/\
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MSSR*,/ZK^7_UZ '44W#^J_E_]>C#^J_E_P#7H =13</ZK^7_ ->C#^J_E_\
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MQ)NSG(^8 X''MBL[6/A[X8UB[N[C4=.:4W9#3Q"YF2&1QT<Q*X0N.S[=W?-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N 1T# 2(  A$! Q$!_\0
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M7<CL[^./$;.QRS%Y,D_]^J;L^''_ $._B+_OJ3_XS74?V]KW_1,%_P"_Z?\
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M6(4Y1]/3]"L.X1EZ^OZGKE%%%<)WA1110 4444 %%%% !1110 4444 %%%%
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M;B[<W_DQZ%X \6:O;:C]@\0:QIUU;3G]W,VH1/(C]@,-D@],=J]9KYDS\/\
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MHH$GC5_]["\_C6I/J7BNXDWR^ ;24C@-)J41./\ OFHOM?B;_HG=A_X,(?\
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MTS341]2ECWM(XRL*G(!QW;N,\>N:\=2X\3^-=3-JL]YJ-S+\YB\S"@#OCA5
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M^6Y8'!8#C)KUOXD_$F70)_['T5D^W[09IR PA!Z*!_>[\]!CUX\^^$^G"_\
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MO!&O>'?#/B(36T::E>P>3;*EP,_=;G(X'+<<YX[5PW_"I/&/_0/B_P# F/\
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:/O,Q/)'7 (&?:NCHI5*\ZBM(*6'A2=XG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00005.jpg
<TEXT>
begin 644 image00005.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  @ "$# 2(  A$! Q$!_\0
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D^S=)B??'9Y_C9NC2>_\ ]8  X#_AG>3_ )_8OS-%>_T4 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
